Combined	O
effects	O
of	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
gene	O
polymorphisms	O
on	O
breast	B-DS
cancer	I-DS
susceptibility	O
and	O
aggressiveness	O

Background	O

Interleukin	B-GP
-	I-GP
8	I-GP
(	O
IL	B-GP
-	I-GP
8	I-GP
/	O
CXCL	B-GP
-	I-GP
8	I-GP
)	O
is	O
a	O
prototype	O
of	O
the	O
ELR	O
+	O
CXC	B-GP
chemokines	I-GP
that	O
play	O
an	O
important	O
role	O
in	O
the	O
promotion	O
and	O
progression	O
of	O
many	O
human	B-OG
cancers	B-DS
including	O
breast	B-DS
cancer	I-DS
.	O

We	O
have	O
recently	O
showed	O
the	O
implication	O
of	O
polymorphism	O
(-	O
251	O
)	O
T	O
/	O
A	O
of	O
IL	B-GP
-	I-GP
8	I-GP
gene	O
in	O
the	O
susceptibility	O
and	O
prognosis	O
of	O
breast	B-DS
carcinoma	I-DS
.	O

IL	B-GP
-	I-GP
8	I-GP
acts	O
through	O
its	O
CXCR1	B-GP
and	O
CXCR2	B-GP
receptors	O
.	O

CXCR2	B-GP
,	O
expressed	O
on	O
the	O
endothelial	O
cells	O
,	O
is	O
the	O
receptor	O
involved	O
in	O
mediating	O
the	O
angiogenic	O
effects	O
of	O
ELR	O
+	O
CXC	B-GP
chemokines	I-GP
and	O
in	O
particular	O
IL	B-GP
-	I-GP
8	I-GP
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
susceptibility	O
and	O
prognostic	O
implications	O
of	O
the	O
genetic	O
variation	O
in	O
CXCR2	B-GP
in	O
breast	B-DS
carcinoma	I-DS
.	O

We	O
also	O
confirmed	O
the	O
implication	O
of	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
T	O
/	O
A	O
polymorphism	O
in	O
a	O
larger	O
cohort	O
.	O

Finally	O
,	O
we	O
combined	O
the	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
variant	O
alleles	O
and	O
analyzed	O
their	O
effects	O
in	O
breast	B-DS
cancer	I-DS
risk	O
and	O
prognosis	O
.	O

Methods	O

We	O
used	O
the	O
allele	O
-	O
specific	O
polymerase	B-GP
chain	O
reaction	O
to	O
characterize	O
the	O
variation	O
of	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
for	O
409	O
unrelated	O
Tunisian	O
patients	O
with	O
breast	B-DS
carcinoma	I-DS
and	O
301	O
healthy	O
control	O
subjects	O
.	O

To	O
estimate	O
the	O
relative	O
risks	O
,	O
Odds	O
ratios	O
and	O
95	O
%	O
confidence	O
intervals	O
were	O
calculated	O
using	O
unconditional	O
logistic	O
regression	O
after	O
adjusting	O
for	O
the	O
known	O
risk	O
factors	O
for	O
breast	B-DS
cancer	I-DS
.	O

Associations	O
of	O
the	O
genetic	O
marker	O
with	O
the	O
rates	O
of	O
breast	B-DS
carcinoma	I-DS
-	O
specific	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
were	O
assessed	O
using	O
univariate	O
and	O
multivariate	O
analyses	O
.	O

Results	O

A	O
highly	O
significant	O
association	O
was	O
found	O
between	O
the	O
homozygous	O
CXCR2	B-GP
(+	O
1208	O
)	O
TT	O
genotype	O
(	O
adjusted	O
OR	O
=	O
2	O
.	O
89	O
;	O
P	O
=	O
0	O
.	O
008	O
)	O
and	O
breast	B-DS
carcinoma	I-DS
.	O

A	O
significantly	O
increased	O
risk	O
of	O
breast	B-DS
carcinoma	I-DS
was	O
associated	O
with	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
allele	O
(	O
adjusted	O
OR	O
=	O
1	O
.	O
86	O
;	O
P	O
=	O
0	O
.	O
001	O
).	O

The	O
presence	O
of	O
two	O
higher	O
risk	O
genotypes	O
(	O
the	O
TA	O
and	O
TT	O
in	O
IL	B-GP
-	I-GP
8	I-GP
,	O
and	O
the	O
TT	O
in	O
CXCR2	B-GP
)	O
significantly	O
increased	O
the	O
risk	O
of	O
developing	O
breast	B-DS
carcinoma	I-DS
(	O
adjusted	O
OR	O
=	O
4	O
.	O
15	O
;	O
P	O
=	O
0	O
.	O
0004	O
).	O

The	O
CXCR2	B-GP
(+	O
1208	O
)	O
T	O
allele	O
manifested	O
a	O
significant	O
association	O
with	O
an	O
aggressive	O
phenotype	O
of	O
breast	B-DS
carcinoma	I-DS
as	O
defined	O
by	O
a	O
large	O
tumor	B-DS
size	O
,	O
a	O
high	O
histological	O
grade	O
,	O
and	O
auxiliary	O
'	O
s	O
lymph	O
node	O
metastasis	O
.	O

A	O
significant	O
association	O
between	O
the	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
allele	O
and	O
the	O
aggressive	O
form	O
of	O
breast	B-DS
carcinoma	I-DS
was	O
also	O
found	O
.	O

Moreover	O
,	O
the	O
presence	O
of	O
the	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
and	O
/	O
or	O
the	O
CXCR2	B-GP
(+	O
1208	O
)	O
T	O
allele	O
showed	O
a	O
significant	O
association	O
with	O
a	O
decreased	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
in	O
breast	B-DS
carcinoma	I-DS
patients	O
.	O

Conclusion	O

Our	O
results	O
indicated	O
that	O
the	O
polymorphisms	O
in	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
genes	O
are	O
associated	O
with	O
increased	O
breast	B-DS
cancer	I-DS
risk	O
,	O
as	O
well	O
as	O
disease	O
progress	O
,	O
supporting	O
our	O
hypothesis	O
for	O
IL	B-GP
-	I-GP
8	I-GP
and	O
ELR	O
+	O
CXC	B-GP
chemokine	I-GP
receptor	I-GP
(	O
CXCR2	B-GP
)	O
involvement	O
in	O
breast	B-DS
cancer	I-DS
pathogenesis	O
.	O

Background	O

Breast	B-DS
cancer	I-DS
is	O
one	O
of	O
the	O
most	O
prevalent	O
cancers	B-DS
in	O
the	O
world	O
.	O

Despite	O
progress	O
made	O
in	O
the	O
last	O
30	O
years	O
in	O
breast	B-DS
cancer	I-DS
screening	O
and	O
treatment	O
,	O
this	O
disease	O
is	O
still	O
responsible	O
for	O
almost	O
half	O
a	O
million	O
deaths	O
per	O
year	O
worldwide	O
.	O

Approximately	O
half	O
of	O
diagnosed	O
patients	O
will	O
eventually	O
develop	O
metastatic	O
disease	O
.	O

Treatment	O
for	O
metastatic	B-DS
breast	I-DS
cancer	I-DS
is	O
palliative	O
,	O
and	O
median	O
life	O
expectancy	O
after	O
recurrence	O
is	O
between	O
24	O
and	O
30	O
months	O
or	O
less	O
[	O
1	O
,	O
2	O
].	O

The	O
etiology	O
of	O
breast	B-DS
cancer	I-DS
is	O
extremely	O
complex	O
and	O
,	O
while	O
not	O
yet	O
elucidated	O
,	O
appears	O
to	O
involve	O
numerous	O
genetic	O
,	O
endocrine	O
and	O
external	O
environmental	O
factors	O
.	O

The	O
role	O
of	O
genetic	O
factors	O
in	O
epidemiology	O
and	O
pathogenesis	O
of	O
both	O
sporadic	O
and	O
familial	O
breast	B-DS
cancer	I-DS
is	O
now	O
well	O
established	O
.	O

Only	O
a	O
small	O
minority	O
(~	O
5	O
%)	O
of	O
patients	O
with	O
breast	B-DS
cancer	I-DS
develop	O
the	O
disease	O
as	O
a	O
result	O
of	O
inheritance	O
of	O
germline	O
mutations	O
in	O
dominant	O
,	O
highly	O
penetrant	O
susceptibility	O
genes	O
such	O
as	O
BRCA1	B-GP
and	O
BRCA2	B-GP
.	O

However	O
,	O
polymorphisms	O
in	O
the	O
genes	O
involved	O
in	O
the	O
complex	O
mechanisms	O
of	O
carcinogenesis	O
may	O
confer	O
low	O
penetrant	O
susceptibility	O
to	O
breast	B-DS
cancer	I-DS
in	O
a	O
significant	O
proportion	O
of	O
the	O
remaining	O
patients	O
[	O
3	O
].	O

The	O
neoplastic	O
transformation	O
,	O
growth	O
,	O
survival	O
,	O
invasion	O
,	O
and	O
metastases	O
are	O
dependent	O
on	O
the	O
establishment	O
of	O
a	O
pro	O
-	O
angiogenic	O
environment	O
.	O

Local	O
angiogenesis	O
is	O
determined	O
by	O
an	O
imbalance	O
in	O
the	O
over	O
-	O
expression	O
of	O
pro	O
-	O
angiogenic	O
factors	O
,	O
as	O
compared	O
to	O
inhibitors	O
of	O
angiogenesis	O
.	O

The	O
CXC	B-GP
chemokine	I-GP
family	O
is	O
the	O
unique	O
group	O
of	O
cytokines	B-GP
known	O
for	O
their	O
ability	O
to	O
behave	O
in	O
a	O
disparate	O
manner	O
in	O
angiogenesis	O
regulation	O
.	O

Several	O
members	O
of	O
the	O
CXC	B-GP
chemokine	I-GP
are	O
potent	O
promoters	O
of	O
angiogenesis	O
,	O
whereas	O
others	O
inhibit	O
the	O
angiogenic	O
process	O
.	O

The	O
disparity	O
in	O
angiogenic	O
activity	O
among	O
CXC	B-GP
chemokine	I-GP
family	O
members	O
is	O
attributed	O
to	O
three	O
amino	O
acid	O
structural	O
domains	O
at	O
the	O
N	O
terminus	O
,	O
Glu	O
-	O
Leu	O
-	O
Arg	O
(	O
ELR	O
),	O
which	O
is	O
present	O
in	O
angiogenic	O
(	O
i	O
.	O
e	O
.,	O
CXCL1	B-GP
,	O
CXCL2	B-GP
,	O
CXCL3	B-GP
,	O
CXCL5	B-GP
,	O
CXCL6	B-GP
,	O
CXCL7	B-GP
,	O
and	O
CXCL8	B-GP
)	O
[	O
4	O
-	O
6	O
],	O
but	O
not	O
angiostatic	O
(	O
i	O
.	O
e	O
.,	O
CXCL4	B-GP
,	O
CXCL9	B-GP
,	O
CXCL10	B-GP
,	O
and	O
CXCL11	B-GP
)	O
CXC	B-GP
chemokines	I-GP
[	O
7	O
].	O

ELR	O
+	O
CXC	B-GP
chemokines	I-GP
play	O
an	O
important	O
role	O
in	O
tumor	B-DS
growth	O
and	O
progression	O
in	O
a	O
number	O
of	O
tumor	B-DS
model	O
systems	O
[	O
8	O
].	O

In	O
particular	O
,	O
interleukin	B-GP
-	I-GP
8	I-GP
(	O
IL	B-GP
-	I-GP
8	I-GP
/	O
CXCL8	B-GP
),	O
which	O
was	O
originally	O
described	O
as	O
a	O
leukocyte	O
chemoattractant	O
[	O
9	O
],	O
was	O
subsequently	O
found	O
to	O
possess	O
mitogenic	O
and	O
angiogenic	O
properties	O
[	O
10	O
,	O
11	O
].	O

Several	O
studies	O
suggested	O
a	O
tendency	O
toward	O
the	O
involvement	O
of	O
IL	B-GP
-	I-GP
8	I-GP
in	O
cancer	B-DS
development	O
[	O
12	O
].	O

Elevated	O
IL	B-GP
-	I-GP
8	I-GP
levels	O
were	O
associated	O
with	O
disease	O
progression	O
and	O
recurrence	O
in	O
human	B-OG
prostate	O
,	O
lung	O
,	O
gastric	O
,	O
and	O
breast	B-DS
cancers	I-DS
[	O
13	O
-	O
16	O
].	O

All	O
angiogenic	O
ELR	O
+	O
CXC	B-GP
chemokines	I-GP
mediate	O
their	O
angiogenic	O
activity	O
through	O
CXCR2	B-GP
[	O
17	O
].	O

Subsequent	O
studies	O
have	O
confirmed	O
the	O
expression	O
of	O
CXCR2	B-GP
,	O
not	O
CXCR1	B-GP
,	O
to	O
be	O
the	O
primary	O
functional	O
chemokine	B-GP
receptor	I-GP
in	O
mediating	O
endothelial	O
cell	O
chemotaxis	O
[	O
18	O
,	O
19	O
].	O

By	O
considering	O
the	O
expression	O
of	O
IL	B-GP
-	I-GP
8	I-GP
by	O
breast	B-DS
cancer	I-DS
cells	O
and	O
CXCR2	B-GP
by	O
large	O
vessel	O
and	O
microvascular	O
endothelial	O
cells	O
[	O
19	O
,	O
20	O
],	O
an	O
autocrine	O
effect	O
for	O
IL	B-GP
-	I-GP
8	I-GP
and	O
the	O
chemokine	B-GP
receptor	I-GP
CXCR2	B-GP
has	O
been	O
suggested	O
.	O

Promoter	O
regions	O
of	O
a	O
number	O
of	O
cytokine	B-GP
genes	O
contain	O
polymorphisms	O
that	O
directly	O
influence	O
cytokine	B-GP
production	O
[	O
21	O
].	O

The	O
IL	B-GP
-	I-GP
8	I-GP
gene	O
is	O
located	O
on	O
chromosome	O
4q13	O
-	O
21	O
and	O
consists	O
of	O
four	O
exons	O
,	O
three	O
introns	O
,	O
and	O
a	O
proximal	O
promoter	O
region	O
[	O
22	O
].	O

Several	O
polymorphisms	O
have	O
been	O
reported	O
in	O
the	O
IL	B-GP
-	I-GP
8	I-GP
gene	O
.	O

Interestingly	O
,	O
IL	B-GP
-	I-GP
8	I-GP
production	O
can	O
be	O
controlled	O
by	O
the	O
-	O
251	O
A	O
/	O
T	O
in	O
the	O
promoter	O
region	O
of	O
this	O
chemokine	B-GP
[	O
23	O
].	O

Recent	O
data	O
revealed	O
that	O
the	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
allele	O
is	O
associated	O
with	O
a	O
high	O
expression	O
level	O
of	O
IL	B-GP
-	I-GP
8	I-GP
protein	O
and	O
a	O
severe	O
neutrophil	O
infiltration	O
[	O
23	O
].	O
Other	O
studies	O
also	O
reported	O
that	O
the	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
T	O
/	O
A	O
polymorphism	O
is	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
developing	O
malignant	B-DS
diseases	I-DS
[	O
24	O
-	O
27	O
].	O

Three	O
single	O
polymorphisms	O
at	O
positions	O
+	O
785	O
C	O
/	O
T	O
,	O
+	O
1208	O
T	O
/	O
C	O
and	O
+	O
1440	O
G	O
/	O
A	O
were	O
reported	O
in	O
the	O
CXCR2	B-GP
gene	O
[	O
28	O
].	O

Several	O
reports	O
indicated	O
that	O
the	O
polymorphism	O
+	O
1208	O
C	O
/	O
T	O
which	O
is	O
located	O
in	O
the	O
non	O
-	O
coding	O
region	O
of	O
CXCR2	B-GP
gene	O
might	O
provide	O
valuable	O
information	O
for	O
the	O
pathogenesis	O
and	O
the	O
susceptibility	O
to	O
chronic	B-DS
inflammatory	I-DS
disease	I-DS
[	O
28	O
,	O
29	O
].	O

Previously	O
we	O
have	O
reported	O
an	O
elevated	O
risk	O
for	O
breast	B-DS
cancer	I-DS
among	O
the	O
Tunisian	O
population	O
(	O
n	O
=	O
308	O
cases	O
and	O
n	O
=	O
236	O
healthy	O
controls	O
)	O
associated	O
with	O
the	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
T	O
/	O
A	O
polymorphism	O
.	O

The	O
implication	O
of	O
this	O
polymorphism	O
in	O
the	O
prognosis	O
of	O
breast	B-DS
carcinoma	I-DS
has	O
also	O
been	O
demonstrated	O
[	O
30	O
].	O

Based	O
on	O
the	O
abundant	O
evidence	O
for	O
the	O
role	O
of	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
in	O
carcinogenesis	O
,	O
we	O
evaluated	O
in	O
this	O
study	O
the	O
association	O
of	O
CXCR2	B-GP
(+	O
1208	O
)	O
C	O
/	O
T	O
gene	O
polymorphism	O
and	O
breast	B-DS
cancer	I-DS
susceptibility	O
and	O
prognosis	O
in	O
Tunisia	O
.	O

Then	O
we	O
used	O
existing	O
and	O
additional	O
genotype	O
data	O
on	O
409	O
breast	B-DS
cancer	I-DS
cases	O
and	O
301	O
healthy	O
controls	O
to	O
examine	O
the	O
potential	O
contribution	O
of	O
the	O
combined	O
genotypes	O
of	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
in	O
breast	B-DS
carcinoma	I-DS
occurrence	O
,	O
clinico	O
-	O
pathological	O
characteristics	O
and	O
prognosis	O
.	O

Methods	O

Patients	O
and	O
controls	O

IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
genotype	O
and	O
allele	O
frequencies	O
were	O
determined	O
in	O
a	O
group	O
of	O
301	O
control	O
subjects	O
and	O
409	O
patients	O
with	O
breast	B-DS
carcinoma	I-DS
.	O

Controls	O
and	O
patients	O
were	O
selected	O
from	O
the	O
same	O
population	O
living	O
in	O
the	O
middle	O
coast	O
of	O
Tunisia	O
and	O
including	O
unrelated	O
subjects	O
.	O

Data	O
on	O
patient	O
,	O
tumour	B-DS
and	O
treatment	O
characteristics	O
at	O
the	O
study	O
entry	O
for	O
each	O
subject	O
were	O
collected	O
from	O
the	O
department	O
of	O
Radiation	O
Oncology	O
and	O
Medical	O
Oncology	O
of	O
Sousse	O
Hospital	O
(	O
Sousse	O
,	O
Tunisia	O
)	O
between	O
1996	O
and	O
2004	O
.	O

They	O
were	O
selected	O
consecutively	O
whenever	O
practically	O
feasible	O
.	O

All	O
patients	O
included	O
in	O
this	O
study	O
had	O
primary	O
breast	B-DS
carcinoma	I-DS
,	O
with	O
unilateral	O
breast	B-DS
tumours	I-DS
and	O
with	O
no	O
family	O
history	O
for	O
the	O
disease	O
.	O

The	O
diagnosis	O
of	O
cancer	B-DS
was	O
confirmed	O
by	O
histopathological	O
analyses	O
.	O

The	O
patients	O
(	O
n	O
=	O
409	O
)	O
had	O
a	O
mean	O
age	O
of	O
48	O
.	O
0	O
±	O
24	O
.	O
3	O
(	O
SD	O
)	O
years	O
.	O

At	O
time	O
of	O
analysis	O
,	O
88	O
patients	O
experienced	O
recurrence	O
(	O
local	O
or	O
distant	O
).	O

Among	O
them	O
,	O
56	O
died	O
from	O
breast	B-DS
carcinoma	I-DS
(	O
63	O
.	O
64	O
%).	O

Table	O
1	O
shows	O
the	O
treatment	O
description	O
of	O
all	O
patients	O
.	O

A	O
total	O
of	O
301	O
healthy	O
women	O
having	O
a	O
mean	O
age	O
of	O
48	O
.	O
0	O
±	O
14	O
.	O
9	O
years	O
,	O
were	O
blood	O
donors	O
with	O
no	O
evidence	O
of	O
any	O
personal	O
or	O
family	O
history	O
of	O
cancer	B-DS
(	O
or	O
other	O
serious	O
illness	O
).	O

Samples	O
from	O
healthy	O
controls	O
were	O
collected	O
consecutively	O
between	O
1996	O
and	O
2004	O
.	O

Control	O
individuals	O
were	O
frequency	O
matched	O
to	O
the	O
expected	O
age	O
distribution	O
of	O
the	O
cases	O
and	O
were	O
from	O
the	O
same	O
geographical	O
area	O
.	O

General	O
characteristics	O
of	O
breast	B-DS
cancer	I-DS
patients	O
and	O
healthy	O
controls	O
women	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

The	O
general	O
characteristics	O
of	O
breast	B-DS
cancer	I-DS
patients	O
and	O
healthy	O
controls	O
from	O
Tunisian	O
women	O
blood	O
donors	O

Characteristics	O
,	O
n	O
(%)	O
a	O

Cases	O

Controls	O

P	O
-	O
valueb	O

Ageb	O
,	O
yr	O

Mean	O
±	O
SD	O

48	O
.	O
0	O
±	O
24	O
.	O

48	O
.	O
0	O
±	O
14	O
.	O
9	O

0	O
.	O
97	O

Body	O
mass	O
index	O
(	O
BMI	O
,	O
kg	O
/	O
m2	O
)	O

24	O
.	O
1	O
±	O
5	O
.	O
4	O

20	O
.	O
6	O
±	O
2	O
.	O
5	O

0	O
.	O
0004	O

History	O
of	O
benign	B-DS
breast	I-DS
disease	I-DS

No	O

241	O
(	O
58	O
.	O
92	O
)	O

154	O
(	O
45	O
.	O
18	O
)	O

Yes	O

168	O
(	O
41	O
.	O
08	O
)	O

147	O
(	O
54	O
.	O
82	O
)	O

0	O
.	O
039	O

Use	O
of	O
oral	O
contraceptive	O

No	O

143	O
(	O
34	O
.	O
96	O
)	O

141	O
(	O
46	O
.	O
84	O
)	O

Yes	O

266	O
(	O
65	O
.	O
04	O
)	O

160	O
(	O
53	O
.	O
16	O
)	O

0	O
.	O
001	O

a	O
Cases	O
:	O
n	O
=	O
409	O
;	O
Controls	O
:	O
n	O
=	O
301	O
.	O

The	O
percentages	O
were	O
shown	O
in	O
the	O
parentheses	O

b	O
Age	O
and	O
BMI	O
were	O
determined	O
by	O
two	O
-	O
sample	O
t	O
tests	O
;	O
history	O
of	O
benign	B-DS
breast	I-DS
disease	I-DS
and	O
oral	O
contraceptive	O
drugs	O
usage	O
were	O
determined	O
by	O
chi	O
-	O
square	O
tests	O
.	O

A	O
detailed	O
description	O
of	O
the	O
clinico	O
-	O
pathological	O
characteristics	O
of	O
breast	B-DS
cancer	I-DS
cases	O
has	O
been	O
reported	O
elsewhere	O
[	O
31	O
]	O
and	O
data	O
on	O
tumor	B-DS
size	O
at	O
diagnosis	O
,	O
nodal	O
status	O
and	O
histological	O
grade	O
are	O
briefly	O
included	O
in	O
Table	O
2	O
.	O

Clinicopathologic	O
Characteristics	O
of	O
the	O
409	O
Breast	B-DS
Carcinoma	I-DS
and	O
the	O
Corresponding	O
Univariate	O
Analysis	O
of	O
death	O
(	O
OVS	O
)	O
and	O
Reccurencea	O
(	O
DFS	O
)	O

Breast	B-DS
carcinoma	I-DS
specific	O
OVS	O

DFS	O

Characteristic	O

%	O

6	O
-	O
year	O
rate	O

P	O
-	O
value	O

6	O
-	O
year	O
rate	O

P	O
-	O
value	O


Clinical	O
tumor	B-DS
size	O

T1	O
-	O
T2	O

67	O
.	O
08	O

82	O
.	O
85	O

70	O

T3	O
-	O
T4	O

32	O
.	O
92	O

62	O
.	O
86	O

<	O
0	O
.	O
001	O

32	O
.	O
86	O

<	O
0	O
.	O
000001	O

Lymph	O
node	O
statusb	O

N	O
(+)	O

46	O
.	O
72	O

84	O
.	O
23	O

71	O
.	O
43	O

N	O
(-)	O

53	O
.	O
28	O

68	O
.	O
57	O

<	O
0	O
.	O
01	O

44	O
.	O
28	O

<	O
0	O
.	O
00001	O

SBR	O
grading	O

1	O
-	O
2	O

60	O
.	O
87	O

79	O
.	O
28	O

69	O
.	O
10	O

3	O

40	O
.	O
13	O

57	O
.	O
28	O

<	O
0	O
.	O
02	O

47	O
.	O
80	O

<	O
0	O
.	O
01	O

Age	O
(	O
yrs	O
)	O

<	O
50	O

57	O
.	O
32	O

78	O
.	O
1	O

70	O
.	O
0	O

≥	O
50	O

42	O
.	O
68	O

75	O
.	O
71	O

NS	O

67	O
.	O
2	O

NS	O

OVS	O
:	O
overall	O
survival	O
;	O
DFS	O
:	O
disease	O
free	O
survival	O
;	O
SBR	O
:	O
Scarff	O
,	O
Bloom	O
and	O
Richardson	O
;	O
NS	O
:	O
not	O
significant	O
.	O

aSix	O
-	O
year	O
survival	O
rates	O
were	O
estimated	O
according	O
to	O
Kaplan	O
and	O
Meier	O
.	O

The	O
log	O
rank	O
test	O
was	O
used	O
to	O
determine	O
whether	O
significant	O
differences	O
(	O
P	O
value	O
)	O
were	O
observed	O
between	O
subgroups	O
of	O
patients	O
.	O

bDetermined	O
based	O
on	O
the	O
pathologic	O
examination	O
.	O

Both	O
patients	O
and	O
controls	O
gave	O
their	O
written	O
consent	O
to	O
participate	O
in	O
the	O
study	O
and	O
to	O
allow	O
their	O
biological	O
samples	O
to	O
be	O
genetically	O
analyzed	O
.	O

Approval	O
for	O
the	O
study	O
was	O
given	O
by	O
the	O
National	O
Ethical	O
Committee	O
.	O

Genomic	O
DNA	O
Extraction	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
leukocytes	O
by	O
a	O
salting	O
procedure	O
[	O
32	O
].	O

Briefly	O
,	O
10	O
ml	O
of	O
blood	O
was	O
mixed	O
with	O
triton	O
lysis	O
buffer	O
(	O
0	O
.	O
32	O
M	O
sucrose	O
,	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
5	O
mM	O
MgCl2	O
,	O
H2O	O
,	O
10	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
7	O
.	O
5	O
).	O

Leukocytes	O
were	O
spun	O
down	O
and	O
washed	O
with	O
H2O	O
.	O

The	O
pellet	O
was	O
incubated	O
with	O
proteinase	B-GP
K	I-GP
at	O
56	O
°	O
C	O
and	O
subsequently	O
salted	O
out	O
at	O
4	O
°	O
C	O
using	O
a	O
substrate	O
NaCl	O
solution	O
.	O

Precipated	O
proteins	O
were	O
removed	O
by	O
centrifugation	O
.	O

The	O
DNA	O
in	O
supernatant	O
fluid	O
was	O
precipated	O
with	O
ethanol	O
.	O

The	O
DNA	O
pellet	O
was	O
dissolved	O
in	O
400	O
μl	O
H2O	O
.	O

IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
T	O
/	O
A	O
and	O
CXCR2	B-GP
(+	O
1208	O
)	O
C	O
/	O
T	O
genotyping	O

An	O
allele	O
-	O
specific	O
polymerase	B-GP
chain	O
reaction	O
(	O
AS	O
-	O
PCR	O
)	O
was	O
used	O
to	O
detect	O
the	O
polymorphisms	O
at	O
positions	O
-	O
251	O
of	O
IL	B-GP
-	I-GP
8	I-GP
gene	O
and	O
+	O
1208	O
of	O
CXCR2	B-GP
gene	O
.	O

For	O
CXCR2	B-GP
genotyping	O
,	O
10	O
μl	O
of	O
PCR	O
reaction	O
mixture	O
consisting	O
of	O
50	O
ng	O
of	O
genomic	O
DNA	O
,	O
0	O
.	O
01	O
mM	O
dNTPs	O
,	O
2	O
mM	O
MgCl2	O
,	O
1	O
×	O
Taq	B-GP
polymerase	I-GP
buffer	O
,	O
0	O
.	O
75	O
μM	O
of	O
each	O
specific	O
/	O
common	O
primer	O
(	O
Amersham	O
,	O
Paris	O
,	O
France	O
),	O
0	O
.	O
2	O
μM	O
of	O
each	O
internal	O
control	O
primer	O
(	O
see	O
Table	O
3	O
for	O
primer	O
sequences	O
)	O
and	O
0	O
.	O
5	O
U	O
of	O
Taq	B-GP
DNA	I-GP
polymerase	I-GP
(	O
Amersham	O
,	O
Paris	O
,	O
France	O
)	O
were	O
employed	O
.	O

As	O
an	O
internal	O
control	O
,	O
the	O
Beta	B-GP
-	I-GP
globin	I-GP
specific	O
primers	O
were	O
included	O
in	O
the	O
AS	O
-	O
PCR	O
(	O
Table	O
2	O
).	O

First	O
,	O
a	O
touch	O
-	O
down	O
procedure	O
25	O
s	O
at	O
95	O
°	O
C	O
was	O
carried	O
out	O
.	O

This	O
was	O
followed	O
by	O
annealing	O
for	O
45	O
s	O
at	O
temperatures	O
decreasing	O
from	O
66	O
°	O
C	O
(	O
four	O
cycles	O
)	O
to	O
60	O
°	O
C	O
(	O
25	O
cycles	O
)	O
and	O
an	O
extension	O
step	O
at	O
72	O
°	O
C	O
for	O
40	O
s	O
.	O

The	O
genotypes	O
of	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
T	O
/	O
A	O
marker	O
were	O
determined	O
as	O
previously	O
reported	O
[	O
30	O
].	O

Primer	O
sequences	O
used	O
for	O
genotyping	O
of	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
T	O
/	O
A	O
and	O
CXCR2	B-GP
(+	O
1208	O
)	O
C	O
/	O
T	O
gene	O
polymorphisms	O
(	O
rs	O
4073	O
and	O
rs	O
1801032	O
)	O

Primer	O
name	O

Primer	O
sequence	O

IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
Common	O

5	O
'-	O
AAT	O
ACG	O
GAG	O
TAT	O
GAC	O
GAA	O
A	O
-	O
3	O
'	O

IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
T	O
(	O
low	O
expresser	O
)	O

5	O
'-	O
CTA	O
GAA	O
ATA	O
AAA	O
AAG	O
CAT	O
ACA	O
T	O
-	O
3	O
'	O

IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
(	O
high	O
expresser	O
)	O

5	O
'-	O
CTA	O
GAA	O
ATA	O
AAA	O
AAG	O
CAT	O
ACA	O
A	O
-	O
3	O
'	O

HGH	B-GP
I	O
CONTROL	O

5	O
'-	O
GCC	O
TTC	O
CCA	O
ACC	O
ATT	O
CCC	O
TTA	O
-	O
3	O
'	O

HGH	B-GP
II	O
CONTROL	O

5	O
'-	O
TCA	O
CGG	O
ATT	O
TCT	O
GTT	O
GTG	O
TTT	O
-	O
3	O
'	O

CXCR2	B-GP
(+	O
1208	O
)	O
Common	O

5	O
'-	O
GTC	O
TTG	O
TGA	O
ATA	O
AGC	O
TGC	O
TAT	O
GA	O
-	O
3	O
'	O

CXCR2	B-GP
(+	O
1208	O
)	O
C	O
Allele	O

5	O
'-	O
CCA	O
TTG	O
TGG	O
TCA	O
CAG	O
GAA	O
GC	O
-	O
3	O
'	O

CXCR2	B-GP
(+	O
1208	O
)	O
T	O
Allele	O

5	O
'-	O
CCA	O
TTG	O
TGG	O
TCA	O
CAG	O
GAA	O
GT	O
-	O
3	O
'	O

Beta	B-GP
Globin	I-GP
I	O

5	O
'-	O
ACA	O
CAA	O
CTG	O
TGT	O
TCA	O
CTA	O
-	O
3	O
'	O

Beta	B-GP
Globin	I-GP
II	O

5	O
'-	O
CAA	O
CTT	O
CAT	O
CCA	O
CGT	O
TCA	O
CC	O
-	O
3	O
'	O

HGH	B-GP
I	O
and	O
II	O
primers	O
amplify	O
HGH	B-GP
(	O
human	B-OG
growth	B-GP
hormone	I-GP
)	O
sequence	O
.	O

The	O
reaction	O
products	O
of	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
gene	O
amplification	O
were	O
loaded	O
onto	O
2	O
%	O
agarose	O
gel	O
containing	O
ethidium	O
bromide	O
,	O
electrophoresed	O
and	O
visualized	O
under	O
UV	O
transillumination	O
.	O

To	O
ensure	O
quality	O
control	O
of	O
all	O
genotyping	O
results	O
,	O
25	O
%	O
of	O
randomly	O
selected	O
samples	O
of	O
both	O
cases	O
and	O
controls	O
were	O
analysed	O
a	O
second	O
time	O
,	O
without	O
finding	O
any	O
discrepancies	O
.	O

Statistical	O
analyses	O

The	O
genotype	O
and	O
allele	O
frequencies	O
of	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
were	O
tested	O
for	O
the	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
for	O
both	O
patient	O
and	O
control	O
groups	O
using	O
the	O
chi	O
-	O
square	O
test	O
.	O

Two	O
-	O
sample	O
t	O
tests	O
and	O
Chi	O
-	O
square	O
tests	O
were	O
used	O
to	O
explore	O
the	O
bivariate	O
association	O
between	O
the	O
status	O
of	O
breast	B-DS
cancer	I-DS
and	O
other	O
covariates	O
for	O
continuous	O
and	O
categorical	O
variables	O
,	O
respectively	O
.	O

Risk	O
association	O
between	O
the	O
genotypes	O
and	O
breast	B-DS
cancer	I-DS
susceptibility	O
and	O
tumours	B-DS
characteristics	O
was	O
estimated	O
by	O
odds	O
ratio	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
95	O
%	O
CI	O
)	O
using	O
multivariate	O
logistic	O
regression	O
analysis	O
.	O

The	O
model	O
for	O
adjusted	O
OR	O
included	O
age	O
at	O
diagnosis	O
,	O
history	O
of	O
benign	B-DS
breast	I-DS
disease	I-DS
,	O
use	O
of	O
oral	O
contraceptive	O
,	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
).	O

Disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
was	O
defined	O
as	O
the	O
time	O
from	O
the	O
date	O
of	O
diagnosis	O
to	O
the	O
first	O
local	O
or	O
distant	O
recurrence	O
or	O
to	O
last	O
contact	O
.	O

Breast	B-DS
carcinoma	I-DS
-	O
specific	O
overall	O
survival	O
(	O
OVS	O
)	O
was	O
defined	O
as	O
the	O
time	O
from	O
the	O
date	O
of	O
diagnosis	O
to	O
death	O
if	O
the	O
patient	O
died	O
from	O
breast	B-DS
carcinoma	I-DS
or	O
to	O
last	O
contact	O
.	O

Six	O
-	O
year	O
survival	O
rates	O
were	O
estimated	O
,	O
and	O
survival	O
curves	O
were	O
plotted	O
according	O
to	O
Kaplan	O
and	O
Meier	O
[	O
33	O
].	O

The	O
differences	O
between	O
groups	O
were	O
calculated	O
by	O
the	O
log	O
-	O
rank	O
test	O
[	O
34	O
].	O

In	O
multivariate	O
analysis	O
,	O
relative	O
risk	O
of	O
recurrence	O
or	O
death	O
from	O
breast	B-DS
carcinoma	I-DS
,	O
95	O
%	O
confidence	O
intervals	O
,	O
and	O
P	O
values	O
for	O
censored	O
survival	O
data	O
were	O
calculated	O
by	O
use	O
of	O
Cox	O
proportional	O
hazards	O
regression	O
Model	O
[	O
35	O
].	O

All	O
P	O
value	O
calculations	O
were	O
two	O
-	O
sided	O
,	O
and	O
P	O
value	O
was	O
considered	O
significant	O
at	O
less	O
than	O
0	O
.	O
05	O
.	O

Only	O
clinicopathologic	O
parameters	O
bearing	O
prognostic	O
significance	O
were	O
included	O
in	O
the	O
Cox	O
model	O
.	O

Clinicopathological	O
parameters	O
were	O
dichotomised	O
as	O
follows	O
:	O
nodal	O
status	O
(≥	O
1	O
versus	O
no	O
positive	O
lymph	O
node	O
),	O
SBR	O
(	O
Scarff	O
,	O
Bloom	O
and	O
Richardson	O
)	O
tumour	B-DS
grade	O
(	O
1	O
-	O
2	O
versus	O
3	O
),	O
clinical	O
tumour	B-DS
size	O
(	O
T1	O
-	O
T2	O
versus	O
T3	O
-	O
T4	O
).	O

The	O
statistical	O
analysis	O
was	O
performed	O
using	O
SEM	O
-	O
STATISTIQUES	O
software	O
(	O
centre	O
Jean	O
Perrin	O
,	O
Clermont	O
-	O
Ferrand	O
,	O
France	O
).	O

Results	O

Polymorphisms	O
in	O
the	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
genes	O
as	O
risk	O
factors	O
for	O
breast	B-DS
carcinoma	I-DS

The	O
breast	B-DS
cancer	I-DS
patients	O
(	O
n	O
=	O
409	O
)	O
and	O
healthy	O
controls	O
(	O
n	O
=	O
301	O
)	O
were	O
all	O
native	O
Tunisian	O
women	O
.	O

The	O
characteristics	O
of	O
the	O
healthy	O
controls	O
and	O
breast	B-DS
cancer	I-DS
patients	O
,	O
including	O
overage	O
ages	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
),	O
history	O
of	O
benign	B-DS
breast	I-DS
disease	I-DS
,	O
and	O
oral	O
contraceptives	O
usage	O
were	O
summarized	O
in	O
Table	O
1	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
cases	O
and	O
controls	O
concerning	O
age	O
.	O

However	O
,	O
BMI	O
,	O
history	O
of	O
benign	B-DS
breast	I-DS
disease	I-DS
,	O
and	O
oral	O
contraceptives	O
usage	O
were	O
significantly	O
different	O
between	O
cases	O
and	O
controls	O
after	O
the	O
statistical	O
testing	O
(	O
see	O
materials	O
and	O
methods	O
).	O

These	O
confounding	O
factors	O
were	O
adjusted	O
in	O
multivariate	O
logistic	O
regression	O
analysis	O
.	O

The	O
genotype	O
distribution	O
and	O
allele	O
frequencies	O
for	O
the	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
T	O
/	O
A	O
and	O
CXCR2	B-GP
(+	O
1208	O
)	O
C	O
/	O
T	O
polymorphisms	O
in	O
all	O
breast	B-DS
carcinoma	I-DS
patients	O
and	O
controls	O
are	O
presented	O
in	O
Table	O
4	O
.	O

The	O
allele	O
frequencies	O
of	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
genes	O
were	O
in	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
in	O
both	O
patients	O
and	O
controls	O
(	O
P	O
=	O
,	O
P	O
=	O
,	O
P	O
=	O
,	O
P	O
=	O
respectively	O
).	O

The	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
T	O
/	O
A	O
and	O
CXCR2	B-GP
(+	O
1208	O
)	O
C	O
/	O
T	O
genotype	O
distributions	O
in	O
Control	O
Subjects	O
and	O
in	O
Patients	O
with	O
Breast	B-DS
Carcinoma	I-DS

Genotypes	O

Patients	O
(	O
n	O
=	O
409	O
)	O

Controls	O
(	O
n	O
=	O
301	O
)	O

Crude	O
OR	O
(	O
95	O
%	O
CI	O
)	O

P	O
-	O
valuea	O

Adjusted	O
OR	O
(	O
95	O
%	O
CI	O
)	O
b	O

P	O
-	O
value	O

n	O
(%)	O

n	O
(%)	O

IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
T	O
/	O
A	O

TT	O

84	O
(	O
20	O
.	O
5	O
)	O

92	O
(	O
30	O
.	O
6	O
)	O

1	O

1	O

TA	O

201	O
(	O
49	O
.	O
2	O
)	O

138	O
(	O
45	O
.	O
8	O
)	O

1	O
.	O
60	O
[	O
1	O
.	O
09	O
-	O
2	O
.	O
34	O
]	O

0	O
.	O
01	O

1	O
.	O
71	O
[	O
1	O
.	O
13	O
-	O
2	O
.	O
55	O
]	O

0	O
.	O
009	O

AA	O

124	O
(	O
30	O
.	O
3	O
)	O

71	O
(	O
23	O
.	O
6	O
)	O

1	O
.	O
91	O
[	O
1	O
.	O
24	O
-	O
2	O
.	O
96	O
]	O

0	O
.	O
002	O

2	O
.	O
03	O
[	O
1	O
.	O
56	O
-	O
3	O
.	O
67	O
]	O

0	O
.	O
001	O

Alleles	O

T	O
-	O
allele	O

369	O
(	O
45	O
.	O
1	O
)	O

322	O
(	O
53	O
.	O
5	O
)	O

A	O
-	O
allele	O

449	O
(	O
54	O
.	O
9	O
)	O

280	O
(	O
46	O
.	O
5	O
)	O

1	O
.	O
40	O
[	O
1	O
.	O
13	O
-	O
1	O
.	O
74	O
]	O

0	O
.	O
001	O

1	O
.	O
86	O
[	O
1	O
.	O
79	O
-	O
2	O
.	O
45	O
]	O

0	O
.	O
001	O


CXCR2	B-GP
(+	O
1208	O
)	O
C	O
/	O
T	O

CC	O

195	O
(	O
46	O
.	O
7	O
)	O

155	O
(	O
51	O
.	O
5	O
)	O

1	O

1	O

CT	O

167	O
(	O
40	O
.	O
8	O
)	O

128	O
(	O
42	O
.	O
5	O
)	O

1	O
.	O
04	O
[	O
0	O
.	O
75	O
-	O
1	O
.	O
43	O
]	O

0	O
.	O
81	O

1	O
.	O
31	O
[	O
0	O
.	O
90	O
-	O
1	O
.	O
69	O
]	O

0	O
.	O
63	O

TT	O

47	O
(	O
11	O
.	O
5	O
)	O

18	O
(	O
6	O
.	O
0	O
)	O

2	O
.	O
08	O
[	O
1	O
.	O
12	O
-	O
3	O
.	O
88	O
]	O

0	O
.	O
01	O

2	O
.	O
89	O
[	O
1	O
.	O
48	O
-	O
4	O
.	O
55	O
]	O

0	O
.	O
008	O

Alleles	O

C	O
-	O
allele	O

557	O
(	O
6	O
.	O
81	O
)	O

438	O
(	O
7	O
.	O
28	O
)	O

T	O
-	O
allele	O

261	O
(	O
31	O
.	O
9	O
)	O

164	O
(	O
27	O
.	O
2	O
)	O

1	O
.	O
25	O
[	O
0	O
.	O
99	O
-	O
1	O
.	O
59	O
]	O

0	O
.	O
05	O

1	O
.	O
37	O
[	O
1	O
.	O
09	O
-	O
1	O
.	O
88	O
]	O

0	O
.	O
03	O

a	O
P	O
-	O
value	O
determined	O
by	O
χ2	O
test	O
.	O

b	O
ORs	O
were	O
adjusted	O
for	O
age	O
,	O
BMI	O
,	O
history	O
of	O
benign	O
disease	O
,	O
and	O
oral	O
contraceptive	O
drugs	O
usage	O
.	O

A	O
significantly	O
higher	O
risk	O
for	O
breast	B-DS
cancer	I-DS
was	O
observed	O
for	O
carriers	O
of	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
AA	O
genotype	O
(	O
adjusted	O
Odds	O
Ratio	O
(	O
OR	O
)	O
=	O
2	O
.	O
03	O
;	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
carriers	O
of	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
TA	O
genotype	O
(	O
OR	O
=	O
1	O
.	O
71	O
;	O
P	O
=	O
0	O
.	O
009	O
).	O

The	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
allele	O
was	O
significantly	O
higher	O
in	O
patients	O
compared	O
to	O
controls	O
(	O
OR	O
=	O
1	O
.	O
86	O
;	O
P	O
=	O
0	O
.	O
001	O
).	O

The	O
genotype	O
frequency	O
of	O
the	O
CXCR2	B-GP
(+	O
1208	O
)	O
TT	O
was	O
0	O
.	O
115	O
in	O
patients	O
with	O
breast	B-DS
carcinoma	I-DS
and	O
0	O
.	O
06	O
in	O
control	O
subjects	O
(	O
OR	O
=	O
2	O
.	O
89	O
;	O
P	O
=	O
0	O
.	O
008	O
).	O

The	O
CXCR2	B-GP
(+	O
1208	O
)	O
T	O
allele	O
was	O
significantly	O
higher	O
in	O
patients	O
compared	O
to	O
controls	O
(	O
OR	O
=	O
1	O
.	O
37	O
;	O
P	O
=	O
0	O
.	O
03	O
)	O
(	O
Table	O
4	O
).	O

Because	O
IL	B-GP
-	I-GP
8	I-GP
functionally	O
interacts	O
with	O
CXCR2	B-GP
we	O
assessed	O
the	O
effect	O
of	O
multiple	O
genotypes	O
on	O
breast	B-DS
carcinoma	I-DS
risk	O
.	O

Through	O
individual	O
investigations	O
of	O
genotypes	O
,	O
we	O
defined	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
TA	O
,	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
AA	O
,	O
and	O
CXCR2	B-GP
(+	O
1208	O
)	O
TT	O
as	O
high	O
-	O
risk	O
genotypes	O
.	O

Table	O
5	O
shows	O
the	O
relation	O
between	O
ORs	O
and	O
the	O
number	O
of	O
high	O
-	O
risk	O
genotypes	O
.	O

In	O
controls	O
,	O
there	O
were	O
no	O
high	O
-	O
risk	O
genotypes	O
in	O
26	O
.	O
91	O
%,	O
1	O
in	O
68	O
.	O
44	O
%	O
and	O
2	O
in	O
4	O
.	O
65	O
%.	O

However	O
,	O
in	O
breast	B-DS
cancer	I-DS
patients	O
,	O
there	O
were	O
no	O
high	O
-	O
risk	O
genotypes	O
in	O
18	O
.	O
3	O
%,	O
1	O
in	O
71	O
.	O
7	O
%	O
and	O
2	O
in	O
10	O
.	O
02	O
%.	O

The	O
presence	O
of	O
1	O
or	O
2	O
high	O
-	O
risk	O
genotypes	O
significantly	O
increased	O
the	O
risk	O
of	O
developing	O
breast	B-DS
carcinoma	I-DS
,	O
with	O
ORs	O
of	O
1	O
.	O
63	O
(	O
95	O
%	O
CI	O
,	O
1	O
.	O
13	O
-	O
2	O
.	O
59	O
;	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
4	O
.	O
15	O
(	O
95	O
%	O
CI	O
,	O
1	O
.	O
92	O
-	O
7	O
.	O
32	O
;	O
P	O
=	O
0	O
.	O
0004	O
),	O
respectively	O
,	O
compared	O
with	O
the	O
absence	O
of	O
the	O
high	O
-	O
risk	O
genotype	O
.	O

Interaction	O
and	O
addictive	O
effects	O
of	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
T	O
/	O
A	O
and	O
CXCR2	B-GP
(+	O
1208	O
)	O
C	O
/	O
T	O
polymorphisms	O
on	O
breast	B-DS
cancer	I-DS
risk	O

Genotypes	O

Patients	O
(	O
n	O
=	O
409	O
)	O

Controls	O
(	O
n	O
=	O
301	O
)	O

Crude	O
OR	O
(	O
95	O
%	O
CI	O
)	O

P	O
-	O
valuea	O

Adjusted	O
OR	O
(	O
95	O
%)	O
b	O

P	O
-	O
value	O

IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)/	O
CXCR2	B-GP
(+	O
1208	O
)	O

n	O
%	O

n	O
%	O

0	O

75	O
(	O
18	O
.	O
34	O
)	O

81	O
(	O
26	O
.	O
91	O
)	O

1	O

1	O

1	O

293	O
(	O
71	O
.	O
64	O
)	O

206	O
(	O
68	O
.	O
44	O
)	O

1	O
.	O
54	O
[	O
1	O
.	O
05	O
-	O
2	O
.	O
24	O
]	O

0	O
.	O
01	O

1	O
.	O
63	O
[	O
1	O
.	O
13	O
-	O
2	O
.	O
59	O
]	O

0	O
.	O
01	O

2	O

41	O
(	O
10	O
.	O
02	O
)	O

14	O
(	O
4	O
.	O
65	O
)	O

3	O
.	O
16	O
[	O
1	O
.	O
52	O
-	O
6	O
.	O
64	O
]	O

0	O
.	O
0006	O

4	O
.	O
15	O
[	O
1	O
.	O
92	O
-	O
7	O
.	O
32	O
]	O

0	O
.	O
0004	O

a	O
P	O
-	O
value	O
determined	O
by	O
χ2	O
test	O
.	O

b	O
ORs	O
were	O
adjusted	O
for	O
age	O
,	O
BMI	O
,	O
history	O
of	O
benign	O
disease	O
,	O
and	O
oral	O
contraceptive	O
drugs	O
usage	O
.	O

The	O
high	O
risk	O
genotypes	O
:	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
T	O
/	O
A	O
=	O
TA	O
/	O
AA	O
;	O
CXCR2	B-GP
(+	O
1208	O
)	O
C	O
/	O
T	O
=	O
TT	O

Prognostic	O
significance	O
of	O
polymorphism	O
in	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
genes	O

Table	O
2	O
shows	O
the	O
clinicopathological	O
characterization	O
.	O

The	O
distribution	O
of	O
the	O
clinicopathological	O
markers	O
was	O
in	O
accordance	O
with	O
previously	O
reported	O
data	O
,	O
indicating	O
that	O
our	O
cohort	O
was	O
representative	O
of	O
breast	B-DS
carcinoma	I-DS
patients	O
.	O

Disease	O
-	O
free	O
survival	O
and	O
breast	B-DS
carcinoma	I-DS
-	O
specific	O
OVS	O
rates	O
were	O
estimated	O
and	O
compared	O
by	O
univariate	O
analysis	O
on	O
these	O
clinicopathological	O
parameters	O
.	O

Significant	O
associations	O
were	O
found	O
for	O
clinical	O
tumor	B-DS
size	O
,	O
lymph	O
node	O
status	O
,	O
and	O
tumor	B-DS
grading	O
with	O
DFS	O
and	O
OVS	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
for	O
age	O
.	O

The	O
distributions	O
of	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
polymorphisms	O
according	O
to	O
the	O
clinico	O
-	O
pathological	O
indices	O
of	O
breast	B-DS
carcinoma	I-DS
severity	O
are	O
presented	O
in	O
Tables	O
6	O
and	O
7	O
.	O

A	O
significant	O
association	O
between	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
allele	O
and	O
large	O
tumor	B-DS
size	O
(	O
T3	O
-	O
T4	O
),	O
high	O
SBR	O
tumor	B-DS
grade	O
(	O
grade	O
3	O
),	O
and	O
lymph	O
node	O
metastases	O
was	O
observed	O
(	O
Table	O
6	O
).	O

In	O
this	O
analysis	O
,	O
we	O
also	O
observed	O
the	O
association	O
of	O
this	O
polymorphism	O
with	O
the	O
hormone	O
status	O
of	O
breast	B-DS
carcinoma	I-DS
.	O

Interestingly	O
,	O
a	O
pronounced	O
association	O
was	O
found	O
between	O
the	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
allele	O
and	O
a	O
negative	O
hormone	O
status	O
(	O
OR	O
=	O
1	O
.	O
82	O
;	O
P	O
=	O
0	O
.	O
0008	O
).	O

Genotype	O
frequencies	O
of	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
T	O
/	O
A	O
polymorphism	O
in	O
relation	O
to	O
pathological	O
indices	O
of	O
Breast	B-DS
Cancer	I-DS
severity	O

Genotypes	O

Number	O
of	O
patients	O
(%)	O

Crude	O
OR	O
(	O
95	O
%	O
CI	O
)	O

P	O
-	O
valuea	O

Adjusted	O
OR	O
(	O
95	O
%	O
CI	O
)	O
b	O

P	O
-	O
value	O

Clinical	O
tumor	B-DS
size	O

T1	O
-	O
T2	O

T3	O
-	O
T4	O

TT	O

65	O
(	O
27	O
.	O
08	O
)	O

37	O
(	O
24	O
.	O
51	O
)	O

1	O

1	O

TA	O

122	O
(	O
50	O
.	O
84	O
)	O

58	O
(	O
38	O
.	O
41	O
)	O

0	O
.	O
84	O
[	O
0	O
.	O
49	O
-	O
1	O
.	O
44	O
]	O

0	O
.	O
48	O

0	O
.	O
74	O
[	O
0	O
.	O
67	O
-	O
1	O
.	O
32	O
]	O

0	O
.	O
87	O

AA	O

53	O
(	O
22	O
.	O
08	O
)	O

56	O
(	O
37	O
.	O
08	O
)	O

1	O
.	O
86	O
[	O
1	O
.	O
03	O
-	O
3	O
.	O
35	O
]	O

0	O
.	O
02	O

1	O
.	O
79	O
[	O
1	O
.	O
11	O
-	O
3	O
.	O
76	O
]	O

0	O
.	O
01	O

Alleles	O

T	O
-	O
allele	O

252	O
(	O
52	O
.	O
50	O
)	O

132	O
(	O
43	O
.	O
71	O
)	O

A	O
-	O
allele	O

228	O
(	O
47	O
.	O
50	O
)	O

170	O
(	O
56	O
.	O
29	O
)	O

1	O
.	O
42	O
[	O
1	O
.	O
05	O
-	O
1	O
.	O
92	O
]	O

0	O
.	O
01	O

1	O
.	O
57	O
[	O
1	O
.	O
32	O
-	O
2	O
.	O
05	O
]	O

0	O
.	O
01	O

Lymph	O
nodes	O
status	O

Negative	O

Positive	O

TT	O

50	O
(	O
27	O
.	O
62	O
)	O

42	O
(	O
19	O
.	O
91	O
)	O

1	O

1	O

TA	O

92	O
(	O
50	O
.	O
83	O
)	O

95	O
(	O
45	O
.	O
02	O
)	O

1	O
.	O
46	O
[	O
0	O
.	O
85	O
-	O
2	O
.	O
52	O
]	O

0	O
.	O
14	O

1	O
.	O
32	O
[	O
0	O
.	O
78	O
-	O
2	O
.	O
01	O
]	O

0	O
.	O
21	O

AA	O

39	O
(	O
21	O
.	O
55	O
)	O

74	O
(	O
35	O
.	O
07	O
)	O

2	O
.	O
26	O
[	O
1	O
.	O
24	O
-	O
4	O
.	O
14	O
]	O

0	O
.	O
004	O

2	O
.	O
59	O
[	O
1	O
.	O
47	O
-	O
5	O
.	O
32	O
]	O

0	O
.	O
002	O

Alleles	O

T	O
-	O
allele	O

192	O
(	O
53	O
.	O
04	O
)	O

179	O
(	O
42	O
.	O
42	O
)	O

A	O
-	O
allele	O

170	O
(	O
46	O
.	O
96	O
)	O

243	O
(	O
57	O
.	O
58	O
)	O

1	O
.	O
53	O
[	O
1	O
.	O
14	O
-	O
2	O
.	O
05	O
]	O

0	O
.	O
002	O

1	O
.	O
58	O
[	O
1	O
.	O
28	O
-	O
2	O
.	O
24	O
]	O

0	O
.	O
001	O

SBR	O
grading	O

1	O
-	O
2	O

3	O

TT	O

66	O
(	O
32	O
.	O
19	O
)	O

46	O
(	O
28	O
.	O
22	O
)	O

1	O

1	O

TA	O

111	O
(	O
54	O
.	O
15	O
)	O

67	O
(	O
41	O
.	O
11	O
)	O

0	O
.	O
87	O
[	O
0	O
.	O
52	O
-	O
1	O
.	O
45	O
]	O

0	O
.	O
55	O

0	O
.	O
91	O
[	O
0	O
.	O
58	O
-	O
1	O
.	O
49	O
]	O

0	O
.	O
34	O

AA	O

28	O
(	O
13	O
.	O
66	O
)	O

50	O
(	O
30	O
.	O
67	O
)	O

2	O
.	O
56	O
[	O
1	O
.	O
35	O
-	O
4	O
.	O
87	O
]	O

0	O
.	O
001	O

2	O
.	O
69	O
[	O
1	O
.	O
52	O
-	O
5	O
.	O
24	O
]	O

0	O
.	O
0009	O

Alleles	O

T	O
-	O
allele	O

243	O
(	O
59	O
.	O
27	O
)	O

159	O
(	O
48	O
.	O
77	O
)	O

A	O
-	O
allele	O

167	O
(	O
40	O
.	O
73	O
)	O

167	O
(	O
51	O
.	O
23	O
)	O

1	O
.	O
53	O
[	O
1	O
.	O
13	O
-	O
2	O
.	O
07	O
]	O

0	O
.	O
004	O

1	O
.	O
66	O
[	O
1	O
.	O
38	O
-	O
2	O
.	O
79	O
]	O

0	O
.	O
002	O

Estrogen	O
receptor	O
status	O

Negative	O

Positive	O

TT	O

41	O
(	O
23	O
.	O
7	O
)	O

51	O
(	O
41	O
.	O
13	O
)	O

1	O

1	O

TA	O

75	O
(	O
43	O
.	O
35	O
)	O

44	O
(	O
35	O
.	O
48	O
)	O

2	O
.	O
12	O
[	O
1	O
.	O
17	O
-	O
3	O
.	O
84	O
]	O

0	O
.	O
007	O

2	O
.	O
01	O
[	O
1	O
.	O
32	O
-	O
3	O
.	O
76	O
]	O

0	O
.	O
006	O

AA	O

57	O
(	O
32	O
.	O
95	O
)	O

29	O
(	O
23	O
.	O
39	O
)	O

2	O
.	O
44	O
[	O
1	O
.	O
28	O
-	O
4	O
.	O
70	O
]	O

0	O
.	O
003	O

2	O
.	O
56	O
[	O
1	O
.	O
68	O
-	O
4	O
.	O
96	O
]	O

0	O
.	O
001	O

Alleles	O

T	O
-	O
allele	O

157	O
(	O
45	O
.	O
38	O
)	O

146	O
(	O
58	O
.	O
87	O
)	O

A	O
-	O
allele	O

189	O
(	O
54	O
.	O
62	O
)	O

102	O
(	O
41	O
.	O
13	O
)	O

1	O
.	O
72	O
[	O
1	O
.	O
22	O
-	O
2	O
.	O
48	O
]	O

0	O
.	O
001	O

1	O
.	O
82	O
[	O
1	O
.	O
96	O
-	O
2	O
.	O
78	O
]	O

0	O
.	O
0008	O

a	O
P	O
-	O
value	O
determined	O
by	O
χ2	O
test	O
.	O

b	O
ORs	O
were	O
adjusted	O
for	O
age	O
,	O
BMI	O
,	O
history	O
of	O
benign	O
disease	O
,	O
and	O
oral	O
contraceptive	O
drugs	O
usage	O
.	O

Furthermore	O
,	O
the	O
frequency	O
of	O
the	O
CXCR2	B-GP
(+	O
1208	O
)	O
T	O
allele	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
a	O
large	O
tumor	B-DS
size	O
(	O
OR	O
=	O
1	O
.	O
98	O
;	O
P	O
=	O
0	O
.	O
0001	O
),	O
with	O
high	O
SBR	O
tumor	B-DS
grade	O
(	O
grade	O
3	O
)	O
(	O
OR	O
=	O
1	O
.	O
67	O
;	O
P	O
=	O
0	O
.	O
01	O
),	O
and	O
with	O
lymph	O
node	O
metastases	O
(	O
OR	O
=	O
1	O
.	O
83	O
;	O
P	O
=	O
0	O
.	O
0008	O
).	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
(-	O
251	O
)	O
A	O
allele	O
of	O
the	O
IL	B-GP
-	I-GP
8	I-GP
gene	O
and	O
the	O
(+	O
1208	O
)	O
T	O
allele	O
of	O
the	O
CXCR2	B-GP
gene	O
are	O
associated	O
with	O
the	O
aggressive	O
forms	O
of	O
breast	B-DS
carcinoma	I-DS
.	O

No	O
association	O
was	O
found	O
between	O
CXCR2	B-GP
gene	O
polymorphism	O
and	O
the	O
hormone	O
status	O
of	O
breast	B-DS
cancer	I-DS
patients	O
(	O
Table	O
7	O
).	O

Genotype	O
frequencies	O
of	O
CXCR2	B-GP
(+	O
1208	O
)	O
C	O
/	O
T	O
polymorphism	O
in	O
relation	O
to	O
pathological	O
indices	O
of	O
Breast	B-DS
Cancer	I-DS
severity	O

Genotypes	O

Number	O
of	O
patients	O
(%)	O

Crude	O
OR	O
(	O
95	O
%	O
CI	O
)	O

P	O
-	O
valuea	O

Adjusted	O
OR	O
(	O
95	O
%	O
CI	O
)	O
b	O

P	O
-	O
value	O

Clinical	O
tumor	B-DS
size	O

T1	O
-	O
T2	O

T3	O
-	O
T4	O

CC	O

117	O
(	O
48	O
.	O
75	O
)	O

51	O
(	O
33	O
.	O
55	O
)	O

1	O

1	O

CT	O

89	O
(	O
37	O
.	O
08	O
)	O

62	O
(	O
40	O
.	O
79	O
)	O

1	O
.	O
60	O
[	O
0	O
.	O
98	O
-	O
2	O
.	O
61	O
]	O

0	O
.	O
04	O

1	O
.	O
73	O
[	O
1	O
.	O
01	O
-	O
2	O
.	O
76	O
]	O

0	O
.	O
03	O

TT	O

34	O
(	O
14	O
.	O
17	O
)	O

39	O
(	O
25	O
.	O
66	O
)	O

2	O
.	O
63	O
[	O
1	O
.	O
44	O
-	O
4	O
.	O
82	O
]	O

0	O
.	O
0006	O

2	O
.	O
89	O
[	O
1	O
.	O
64	O
-	O
5	O
.	O
06	O
]	O

0	O
.	O
0004	O

Alleles	O

C	O
-	O
allele	O

323	O
(	O
67	O
.	O
29	O
)	O

164	O
(	O
53	O
.	O
95	O
)	O

T	O
-	O
allele	O

157	O
(	O
32	O
.	O
71	O
)	O

140	O
(	O
46	O
.	O
05	O
)	O

1	O
.	O
76	O
[	O
1	O
.	O
29	O
-	O
2	O
.	O
39	O
]	O

0	O
.	O
0001	O

1	O
.	O
98	O
[	O
1	O
.	O
47	O
-	O
2	O
.	O
56	O
]	O

0	O
.	O
0001	O


Lymph	O
nodes	O
status	O

Negative	O

Positive	O

CC	O

94	O
(	O
51	O
.	O
93	O
)	O

81	O
(	O
38	O
.	O
39	O
)	O

1	O

1	O

CT	O

69	O
(	O
38	O
.	O
12	O
)	O

89	O
(	O
42	O
.	O
18	O
)	O

1	O
.	O
50	O
[	O
0	O
.	O
95	O
-	O
2	O
.	O
36	O
]	O

0	O
.	O
06	O

1	O
.	O
45	O
[	O
0	O
.	O
98	O
-	O
2	O
.	O
27	O
]	O

0	O
.	O
07	O

TT	O

18	O
(	O
9	O
.	O
95	O
)	O

41	O
(	O
19	O
.	O
43	O
)	O

2	O
.	O
64	O
[	O
1	O
.	O
35	O
-	O
5	O
.	O
21	O
]	O

0	O
.	O
002	O

2	O
.	O
72	O
[	O
1	O
.	O
44	O
-	O
5	O
.	O
43	O
]	O

0	O
.	O
001	O

Alleles	O

C	O
-	O
allele	O

257	O
(	O
70	O
.	O
99	O
)	O

251	O
(	O
59	O
.	O
48	O
)	O

T	O
-	O
allele	O

105	O
(	O
29	O
.	O
01	O
)	O

171	O
(	O
40	O
.	O
52	O
)	O

1	O
.	O
67	O
[	O
1	O
.	O
22	O
-	O
2	O
.	O
27	O
]	O

0	O
.	O
0007	O

1	O
.	O
83	O
[	O
1	O
.	O
32	O
-	O
2	O
.	O
46	O
]	O

0	O
.	O
0008	O


SBR	O
grading	O

1	O
-	O
2	O

3	O

CC	O

91	O
(	O
44	O
.	O
39	O
)	O

63	O
(	O
38	O
.	O
18	O
)	O

1	O

1	O

CT	O

85	O
(	O
41	O
.	O
46	O
)	O

64	O
(	O
38	O
.	O
78	O
)	O

1	O
.	O
09	O
[	O
0	O
.	O
67	O
-	O
1	O
.	O
76	O
]	O

0	O
.	O
71	O

1	O
.	O
12	O
[	O
0	O
.	O
78	O
-	O
1	O
.	O
89	O
]	O

0	O
.	O
65	O

TT	O

29	O
(	O
14	O
.	O
15	O
)	O

38	O
(	O
23	O
.	O
03	O
)	O

1	O
.	O
89	O
[	O
1	O
.	O
02	O
-	O
3	O
.	O
53	O
]	O

0	O
.	O
03	O

1	O
.	O
98	O
[	O
1	O
.	O
15	O
-	O
3	O
.	O
79	O
]	O

0	O
.	O
02	O

Alleles	O

C	O
-	O
allele	O

267	O
(	O
65	O
.	O
12	O
)	O

190	O
(	O
57	O
.	O
58	O
)	O

T	O
-	O
allele	O

143	O
(	O
34	O
.	O
88	O
)	O

140	O
(	O
42	O
.	O
42	O
)	O

1	O
.	O
38	O
[	O
1	O
.	O
01	O
-	O
1	O
.	O
87	O
]	O

0	O
.	O
03	O

1	O
.	O
67	O
[	O
1	O
.	O
08	O
-	O
2	O
.	O
03	O
]	O

0	O
.	O
01	O


Estrogen	O
receptor	O
status	O

Positive	O

Negative	O

CC	O

50	O
(	O
30	O
.	O
87	O
)	O

48	O
(	O
33	O
.	O
33	O
)	O

1	O

1	O

CT	O

76	O
(	O
46	O
.	O
91	O
)	O

60	O
(	O
41	O
.	O
67	O
)	O

1	O
.	O
22	O
[	O
0	O
.	O
70	O
-	O
2	O
.	O
12	O
]	O

0	O
.	O
46	O

1	O
.	O
34	O
[	O
0	O
.	O
78	O
-	O
2	O
.	O
34	O
]	O

0	O
.	O
35	O

TT	O

36	O
(	O
22	O
.	O
22	O
)	O

36	O
(	O
25	O
.	O
00	O
)	O

0	O
.	O
96	O
[	O
0	O
.	O
50	O
-	O
1	O
.	O
85	O
]	O

0	O
.	O
89	O

0	O
.	O
87	O
[	O
0	O
.	O
54	O
-	O
1	O
.	O
89	O
]	O

0	O
.	O
85	O

Alleles	O

C	O
-	O
allele	O

176	O
(	O
54	O
.	O
32	O
)	O

156	O
(	O
54	O
.	O
17	O
)	O

T	O
-	O
allele	O

148	O
(	O
45	O
.	O
68	O
)	O

132	O
(	O
45	O
.	O
83	O
)	O

0	O
.	O
99	O
[	O
0	O
.	O
71	O
-	O
1	O
.	O
38	O
]	O

0	O
.	O
96	O

0	O
.	O
95	O
[	O
0	O
.	O
66	O
-	O
1	O
.	O
27	O
]	O

0	O
.	O
87	O

a	O
P	O
-	O
value	O
determined	O
by	O
χ2	O
test	O
.	O

b	O
ORs	O
were	O
adjusted	O
for	O
age	O
,	O
BMI	O
,	O
history	O
of	O
benign	O
disease	O
,	O
and	O
oral	O
contraceptive	O
drugs	O
usage	O
.	O

When	O
the	O
relationship	O
between	O
the	O
distribution	O
of	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
genotypes	O
in	O
all	O
patients	O
and	O
the	O
survival	O
(	O
OVS	O
and	O
DFS	O
)	O
was	O
tested	O
,	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
OVS	O
and	O
the	O
DFS	O
Kaplan	O
-	O
Meier	O
survival	O
curves	O
for	O
the	O
different	O
polymorphisms	O
.	O

The	O
breast	B-DS
carcinoma	I-DS
-	O
specific	O
OVS	O
was	O
significantly	O
shorter	O
among	O
patients	O
carrying	O
the	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
allele	O
(	O
Figure	O
1A	O
).	O

The	O
estimated	O
3	O
-	O
and	O
6	O
-	O
year	O
breast	B-DS
carcinoma	I-DS
-	O
specific	O
OVS	O
rates	O
for	O
the	O
group	O
of	O
patients	O
carrying	O
or	O
not	O
carrying	O
the	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
allele	O
were	O
respectively	O
91	O
.	O
4	O
and	O
77	O
.	O
1	O
%	O
versus	O
75	O
.	O
7	O
and	O
45	O
.	O
7	O
%	O
(	O
log	O
rank	O
test	O
,	O
P	O
<	O
0	O
.	O
002	O
).	O

The	O
estimated	O
3	O
-	O
and	O
6	O
-	O
year	O
DFS	O
rates	O
in	O
the	O
group	O
of	O
patients	O
with	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
allele	O
were	O
81	O
.	O
4	O
%	O
and	O
50	O
%	O
versus	O
95	O
.	O
7	O
%	O
and	O
88	O
.	O
5	O
%	O
in	O
the	O
group	O
of	O
patients	O
without	O
the	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
allele	O
(	O
log	O
rank	O
test	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

Breast	B-DS
carcinoma	I-DS
-	O
specific	O
overall	O
survival	O
(	O
A	O
)	O
and	O
disease	O
-	O
free	O
survival	O
(	O
B	O
)	O
of	O
409	O
breast	B-DS
carcinoma	I-DS
patients	O
according	O
to	O
the	O
presence	O
or	O
absence	O
of	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
allele	O
(	O
P	O
denotes	O
the	O
log	O
-	O
rank	O
test	O
value	O
).	O

As	O
shown	O
in	O
Figure	O
2	O
,	O
the	O
breast	B-DS
carcinoma	I-DS
specific	O
OVS	O
and	O
DFS	O
were	O
significantly	O
shorter	O
in	O
the	O
group	O
of	O
patients	O
carrying	O
CXCR2	B-GP
(+	O
1208	O
)	O
T	O
allele	O
.	O

The	O
estimated	O
3	O
-	O
and	O
6	O
-	O
year	O
breast	B-DS
carcinoma	I-DS
OVS	O
rate	O
in	O
the	O
group	O
of	O
patients	O
carrying	O
CXCR2	B-GP
(+	O
1208	O
)	O
T	O
allele	O
were	O
,	O
respectively	O
,	O
87	O
.	O
1	O
and	O
65	O
.	O
7	O
%	O
versus	O
95	O
.	O
7	O
%	O
and	O
90	O
%	O
for	O
those	O
not	O
carrying	O
the	O
(+	O
1208	O
)	O
T	O
allele	O
(	O
log	O
rank	O
test	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

The	O
estimated	O
3	O
-	O
and	O
6	O
-	O
year	O
DFS	O
rates	O
in	O
the	O
group	O
of	O
patients	O
with	O
CXCR2	B-GP
(+	O
1208	O
)	O
T	O
allele	O
were	O
74	O
.	O
3	O
%	O
and	O
50	O
%	O
versus	O
90	O
%	O
and	O
61	O
.	O
4	O
%	O
in	O
the	O
group	O
of	O
patients	O
without	O
the	O
CXCR2	B-GP
(+	O
1208	O
)	O
T	O
allele	O
(	O
log	O
rank	O
test	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O

Breast	B-DS
carcinoma	I-DS
-	O
specific	O
overall	O
survival	O
(	O
C	O
)	O
and	O
disease	O
-	O
free	O
survival	O
(	O
D	O
)	O
of	O
409	O
breast	B-DS
carcinoma	I-DS
patients	O
according	O
to	O
the	O
presence	O
or	O
absence	O
of	O
CXCR2	B-GP
(+	O
1208	O
)	O
T	O
allele	O
(	O
P	O
denotes	O
the	O
log	O
-	O
rank	O
test	O
value	O
).	O

Multivariate	O
analyses	O
were	O
undertaken	O
to	O
evaluate	O
the	O
importance	O
of	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
markers	O
in	O
the	O
recurrence	O
risk	O
and	O
death	O
compared	O
with	O
the	O
clinicopathological	O
parameters	O
.	O

Introducing	O
the	O
genetic	O
and	O
the	O
clinicopathological	O
parameters	O
bearing	O
prognostic	O
significance	O
we	O
tested	O
the	O
Cox	O
model	O
.	O

No	O
genetic	O
and	O
clinicopathological	O
parameters	O
were	O
selected	O
for	O
OVS	O
and	O
DFS	O
.	O

Further	O
analyses	O
were	O
conducted	O
to	O
explore	O
whether	O
combined	O
high	O
-	O
risk	O
genotypes	O
of	O
the	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
genes	O
were	O
associated	O
with	O
clinicopathological	O
indices	O
and	O
survival	O
among	O
patients	O
.	O

No	O
additional	O
effect	O
was	O
found	O
between	O
the	O
presence	O
of	O
more	O
than	O
one	O
high	O
-	O
risk	O
genotype	O
and	O
indices	O
of	O
an	O
aggressive	O
form	O
of	O
breast	B-DS
carcinoma	I-DS
(	O
nodal	O
status	O
,	O
SBR	O
,	O
tumor	B-DS
grade	O
)	O
or	O
OVS	O
and	O
DFS	O
(	O
data	O
not	O
shown	O
).	O

Discussion	O

The	O
ELR	O
+	O
CXC	B-GP
chemokines	I-GP
play	O
an	O
important	O
role	O
in	O
tumor	B-DS
growth	O
and	O
progression	O
in	O
a	O
number	O
of	O
tumor	B-DS
model	O
systems	O
.	O

IL	B-GP
-	I-GP
8	I-GP
/	O
CXCL8	B-GP
was	O
the	O
first	O
described	O
angiogenic	O
,	O
mitogenic	O
,	O
and	O
motogenic	O
chemokine	B-GP
in	O
various	O
cancer	B-DS
models	O
and	O
is	O
the	O
prototype	O
of	O
ELR	O
+	O
CXC	B-GP
chemokines	I-GP
[	O
8	O
,	O
10	O
-	O
13	O
].	O

This	O
chemokine	B-GP
was	O
initially	O
discovered	O
on	O
the	O
basis	O
of	O
its	O
ability	O
to	O
induce	O
mobilization	O
of	O
neutrophils	O
and	O
lymphocytes	O
in	O
vivo	O
[	O
9	O
].	O

Like	O
the	O
basic	B-GP
fibroblast	I-GP
growth	I-GP
factor	I-GP
(	O
bFGF	B-GP
)	O
and	O
the	O
vascular	B-GP
endothelial	I-GP
growth	I-GP
factor	I-GP
(	O
VEGF	B-GP
),	O
it	O
is	O
a	O
strong	O
angiogenesis	O
inducer	O
.	O

IL	B-GP
-	I-GP
8	I-GP
mediates	O
endothelial	O
cell	O
chemotaxis	O
and	O
proliferation	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
36	O
].	O

The	O
fact	O
that	O
all	O
ELR	O
+	O
CXC	B-GP
chemokines	I-GP
mediate	O
angiogenesis	O
highlights	O
the	O
importance	O
of	O
identifying	O
a	O
common	O
receptor	O
that	O
mediates	O
their	O
biological	O
functions	O
in	O
promoting	O
angiogenesis	O
.	O

The	O
candidate	O
CXC	B-GP
chemokine	I-GP
receptors	I-GP
are	O
CXCR1	B-GP
and	O
CXCR2	B-GP
.	O

Only	O
CXCL	B-GP
-	I-GP
8	I-GP
/	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCL	B-GP
-	I-GP
6	I-GP
specifically	O
bind	O
to	O
CXCR1	B-GP
whereas	O
all	O
ELR	O
+	O
CXC	B-GP
chemokines	I-GP
bind	O
to	O
CXCR2	B-GP
.	O

There	O
is	O
evidence	O
that	O
CXCR2	B-GP
is	O
implicated	O
in	O
the	O
angiogenic	O
activity	O
of	O
ELR	O
+	O
CXC	B-GP
chemokines	I-GP
[	O
18	O
,	O
36	O
].	O

In	O
recent	O
years	O
,	O
several	O
studies	O
have	O
shown	O
that	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
are	O
overexpressed	O
in	O
a	O
range	O
of	O
human	B-OG
cancers	B-DS
including	O
renal	O
,	O
prostate	O
,	O
pancreatic	O
,	O
colon	O
,	O
nasopharyngeal	O
,	O
and	O
gastric	B-DS
cancers	I-DS
[	O
37	O
-	O
41	O
].	O

IL	B-GP
-	I-GP
8	I-GP
and	O
its	O
receptors	O
were	O
detected	O
on	O
breast	B-DS
tumor	I-DS
cells	O
and	O
endothelial	O
cells	O
of	O
tumor	B-DS
vessels	O
[	O
19	O
-	O
21	O
].	O

In	O
addition	O
,	O
IL	B-GP
-	I-GP
8	I-GP
levels	O
are	O
significantly	O
higher	O
in	O
breast	B-DS
cancer	I-DS
patients	O
compared	O
with	O
healthy	O
controls	O
[	O
42	O
].	O

Ben	O
-	O
Baruch	O
et	O
al	O
have	O
demonstrated	O
that	O
,	O
aside	O
the	O
role	O
of	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
in	O
mediating	O
the	O
recruitment	O
of	O
the	O
tumor	B-DS
-	O
infiltrating	O
leucocytes	O
to	O
tumor	B-DS
site	O
,	O
their	O
expression	O
may	O
also	O
affect	O
neoplastic	O
proliferation	O
and	O
metastasis	O
[	O
43	O
].	O

IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
overexpression	O
may	O
present	O
a	O
risk	O
factor	O
in	O
the	O
development	O
and	O
progression	O
of	O
solid	B-DS
tumors	I-DS
.	O

Several	O
polymorphisms	O
have	O
been	O
identified	O
in	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
genes	O
.	O

Among	O
these	O
,	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
T	O
/	O
A	O
polymorphism	O
exerts	O
one	O
of	O
the	O
greatest	O
influences	O
on	O
IL	B-GP
-	I-GP
8	I-GP
production	O
.	O

Polymorphism	O
+	O
1208	O
C	O
/	O
T	O
of	O
the	O
CXCR2	B-GP
gene	O
is	O
implicated	O
in	O
the	O
susceptibility	O
to	O
and	O
the	O
pathogenesis	O
of	O
chronic	B-DS
inflammatory	I-DS
diseases	I-DS
[	O
28	O
,	O
29	O
].	O

Recently	O
,	O
we	O
have	O
showed	O
that	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
T	O
/	O
A	O
polymorphism	O
may	O
be	O
a	O
genetic	O
risk	O
factor	O
for	O
breast	B-DS
cancer	I-DS
onset	O
and	O
severity	O
in	O
the	O
Tunisian	O
population	O
[	O
30	O
].	O

Our	O
current	O
study	O
aims	O
to	O
confirm	O
these	O
results	O
in	O
a	O
larger	O
cohort	O
and	O
to	O
determine	O
whether	O
there	O
is	O
any	O
association	O
between	O
the	O
genetic	O
polymorphism	O
of	O
the	O
CXCR2	B-GP
and	O
both	O
individual	O
susceptibility	O
to	O
and	O
prognosis	O
of	O
breast	B-DS
carcinoma	I-DS
.	O

Based	O
on	O
the	O
intertwined	O
and	O
interactive	O
roles	O
that	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
play	O
at	O
the	O
molecular	O
level	O
in	O
the	O
angiogenic	O
pathway	O
,	O
we	O
further	O
hypothesized	O
a	O
priori	O
that	O
the	O
joint	O
effect	O
of	O
genetic	O
variants	O
in	O
these	O
angiogenesis	O
regulators	O
may	O
increase	O
breast	B-DS
cancer	I-DS
risk	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
comparison	O
of	O
genotype	O
frequencies	O
of	O
IL	B-GP
-	I-GP
8	I-GP
for	O
breast	B-DS
carcinoma	I-DS
patients	O
and	O
control	O
subjects	O
indicates	O
an	O
increase	O
of	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
TA	O
and	O
AA	O
genotypes	O
.	O

Consequently	O
,	O
the	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
allele	O
frequency	O
was	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
patients	O
compared	O
with	O
controls	O
.	O

These	O
results	O
confirmed	O
our	O
previous	O
findings	O
in	O
a	O
smaller	O
subset	O
of	O
cases	O
and	O
controls	O
[	O
31	O
].	O

CXCR2	B-GP
genotype	O
analysis	O
revealed	O
that	O
carriers	O
of	O
CXCR2	B-GP
(+	O
1208	O
)	O
TT	O
homozygous	O
genotype	O
are	O
significantly	O
over	O
-	O
represented	O
among	O
breast	B-DS
cancer	I-DS
cases	O
(	O
OR	O
=	O
2	O
.	O
08	O
;	O
P	O
=	O
0	O
.	O
01	O
).	O

Despite	O
the	O
great	O
interest	O
in	O
CXCR2	B-GP
biological	O
properties	O
,	O
little	O
is	O
known	O
about	O
the	O
functional	O
importance	O
of	O
single	O
nucleotide	O
polymorphisms	O
in	O
its	O
gene	O
.	O

This	O
result	O
indicates	O
that	O
CXCR2	B-GP
gene	O
polymorphism	O
could	O
be	O
considered	O
as	O
a	O
susceptibility	O
gene	O
in	O
breast	B-DS
cancer	I-DS
development	O
.	O

These	O
findings	O
suggested	O
that	O
individual	O
genetic	O
polymorphisms	O
of	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
were	O
associated	O
with	O
breast	B-DS
carcinoma	I-DS
risk	O
.	O

However	O
,	O
the	O
combination	O
of	O
these	O
genotypes	O
showed	O
a	O
marked	O
association	O
with	O
breast	B-DS
carcinoma	I-DS
risk	O
.	O

We	O
defined	O
the	O
TA	O
and	O
AA	O
genotypes	O
of	O
the	O
IL	B-GP
-	I-GP
8	I-GP
gene	O
and	O
the	O
TT	O
genotype	O
of	O
the	O
CXCR2	B-GP
gene	O
as	O
high	O
-	O
risk	O
genotypes	O
according	O
to	O
the	O
individual	O
genotype	O
analysis	O
.	O

Breast	B-DS
carcinoma	I-DS
risk	O
significantly	O
increased	O
according	O
to	O
the	O
number	O
of	O
high	O
-	O
risk	O
genotypes	O
.	O

There	O
was	O
a	O
63	O
%	O
increase	O
in	O
breast	B-DS
cancer	I-DS
(	O
OR	O
=	O
1	O
.	O
63	O
;	O
P	O
=	O
0	O
.	O
01	O
)	O
for	O
the	O
presence	O
of	O
one	O
high	O
-	O
risk	O
genotype	O
.	O

The	O
risk	O
was	O
4	O
.	O
15	O
(	O
P	O
=	O
0	O
.	O
0004	O
)	O
for	O
individuals	O
with	O
two	O
high	O
-	O
risk	O
genotypes	O
.	O

These	O
data	O
,	O
taken	O
together	O
,	O
suggest	O
that	O
there	O
is	O
evidence	O
of	O
a	O
gene	O
-	O
dosage	O
effect	O
.	O

The	O
assessment	O
of	O
the	O
prognostic	O
value	O
of	O
IL	B-GP
-	I-GP
8	I-GP
genetic	O
marker	O
in	O
breast	B-DS
carcinoma	I-DS
confirmed	O
the	O
results	O
of	O
our	O
previous	O
study	O
and	O
indicated	O
that	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
allele	O
is	O
highly	O
associated	O
with	O
aggressive	O
forms	O
of	O
breast	B-DS
carcinoma	I-DS
as	O
defined	O
by	O
large	O
tumor	B-DS
size	O
,	O
high	O
grade	O
and	O
lymph	O
node	O
metastases	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
also	O
examined	O
for	O
the	O
first	O
time	O
the	O
relationship	O
between	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
T	O
/	O
A	O
polymorphism	O
and	O
the	O
hormonal	O
status	O
.	O

Interestingly	O
,	O
we	O
observed	O
a	O
significant	O
association	O
between	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
allele	O
and	O
a	O
negative	O
hormonal	O
status	O
(	O
P	O
=	O
0	O
.	O
0008	O
).	O

Furthermore	O
,	O
we	O
investigated	O
the	O
association	O
of	O
the	O
CXCR2	B-GP
(+	O
1208	O
)	O
C	O
/	O
T	O
polymorphism	O
with	O
markers	O
of	O
tumor	B-DS
progression	O
.	O

Our	O
results	O
showed	O
a	O
significant	O
association	O
between	O
CXCR2	B-GP
(+	O
1208	O
)	O
T	O
allele	O
and	O
a	O
large	O
tumor	B-DS
size	O
(	O
P	O
=	O
0	O
.	O
0001	O
),	O
high	O
SBR	O
tumor	B-DS
grade	O
(	O
P	O
=	O
0	O
.	O
01	O
),	O
and	O
lymph	O
node	O
metastases	O
(	O
P	O
=	O
0	O
.	O
0008	O
).	O

More	O
interestingly	O
,	O
we	O
showed	O
that	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
and	O
CXCR2	B-GP
(+	O
1208	O
)	O
T	O
alleles	O
were	O
associated	O
with	O
a	O
shorter	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
and	O
,	O
therefore	O
,	O
with	O
a	O
poor	O
prognosis	O
in	O
breast	B-DS
carcinoma	I-DS
.	O

Given	O
the	O
importance	O
of	O
IL	B-GP
-	I-GP
8	I-GP
and	O
CXCR2	B-GP
in	O
angiogenesis	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
polymorphisms	O
-	O
251	O
T	O
/	O
A	O
in	O
IL	B-GP
-	I-GP
8	I-GP
gene	O
and	O
(+	O
1208	O
)	O
C	O
/	O
T	O
in	O
CXCR2	B-GP
gene	O
and	O
breast	B-DS
carcinoma	I-DS
.	O

The	O
results	O
show	O
that	O
these	O
polymorphisms	O
may	O
be	O
related	O
to	O
breast	B-DS
carcinoma	I-DS
development	O
and	O
progression	O
.	O

In	O
agreement	O
with	O
our	O
findings	O
,	O
several	O
studies	O
reported	O
a	O
relationship	O
between	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
T	O
/	O
A	O
and	O
CXCR2	B-GP
(+	O
1208	O
)	O
C	O
/	O
T	O
genes	O
polymorphisms	O
and	O
human	B-OG
cancer	B-DS
.	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
allele	O
,	O
which	O
resulted	O
in	O
higher	O
IL	B-GP
-	I-GP
8	I-GP
secretion	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
and	O
poor	O
prognosis	O
of	O
colorectal	B-DS
cancer	I-DS
,	O
prostate	B-DS
cancer	I-DS
,	O
and	O
gastric	B-DS
cancer	I-DS
[	O
24	O
-	O
26	O
,	O
44	O
].	O

Similarly	O
,	O
we	O
reported	O
in	O
a	O
previous	O
study	O
that	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
allele	O
held	O
a	O
higher	O
risk	O
of	O
nasopharyngeal	B-DS
carcinoma	I-DS
and	O
was	O
highly	O
associated	O
with	O
aggressive	O
forms	O
and	O
poor	O
prognosis	O
[	O
27	O
].	O

Regarding	O
breast	B-DS
carcinoma	I-DS
,	O
the	O
current	O
study	O
confirmed	O
our	O
previous	O
results	O
obtained	O
in	O
a	O
smaller	O
cohort	O
and	O
is	O
also	O
in	O
agreement	O
with	O
Kamali	O
-	O
Sarvestani	O
et	O
al	O
.	O
who	O
reported	O
that	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
allele	O
carriers	O
had	O
a	O
significantly	O
higher	O
risk	O
of	O
breast	B-DS
carcinoma	I-DS
than	O
non	O
carriers	O
in	O
the	O
Iranian	O
population	O
[	O
45	O
].	O

Recently	O
,	O
few	O
studies	O
have	O
shown	O
the	O
relationship	O
between	O
CXCR2	B-GP
gene	O
polymorphisms	O
and	O
human	B-OG
cancer	B-DS
[	O
46	O
,	O
47	O
].	O

The	O
CXCR2	B-GP
gene	O
polymorphisms	O
were	O
associated	O
with	O
pancreatic	B-DS
cancer	I-DS
but	O
not	O
with	O
prostate	O
and	O
breast	B-DS
cancer	I-DS
[	O
46	O
,	O
47	O
].	O

Kamali	O
-	O
Sarvestini	O
et	O
al	O
.	O
have	O
demonstrated	O
that	O
CXCR2	B-GP
(+	O
1208	O
)	O
C	O
/	O
T	O
polymorphism	O
is	O
not	O
associated	O
with	O
breast	B-DS
cancer	I-DS
[	O
45	O
].	O

This	O
result	O
is	O
in	O
contrast	O
with	O
our	O
findings	O
.	O

There	O
is	O
now	O
convincing	O
evidence	O
that	O
these	O
correlations	O
between	O
IL	B-GP
-	I-GP
8	I-GP
A	O
allele	O
and	O
cancer	B-DS
risk	O
result	O
from	O
an	O
increased	O
level	O
of	O
IL	B-GP
-	I-GP
8	I-GP
protein	O
,	O
which	O
may	O
have	O
an	O
impact	O
on	O
cancer	B-DS
development	O
and	O
progression	O
via	O
the	O
regulation	O
of	O
immune	O
response	O
and	O
pathways	O
of	O
tumor	B-DS
angiogenesis	O
.	O

IL	B-GP
-	I-GP
8	I-GP
is	O
an	O
important	O
chemoattractant	O
that	O
promotes	O
inflammatory	O
processes	O
[	O
9	O
].	O

The	O
IL	B-GP
-	I-GP
8	I-GP
receptors	I-GP
CXCR1	B-GP
and	O
CXCR2	B-GP
have	O
been	O
reported	O
to	O
be	O
present	O
in	O
a	O
variety	O
of	O
cell	O
types	O
including	O
inflammatory	O
cells	O
,	O
endothelial	O
cells	O
,	O
and	O
fibroblasts	O
[	O
46	O
].	O

Consequently	O
,	O
IL	B-GP
-	I-GP
8	I-GP
is	O
a	O
major	O
contributing	O
factor	O
involved	O
in	O
the	O
initiation	O
and	O
amplification	O
of	O
the	O
inflammatory	O
response	O
via	O
its	O
receptors	O
[	O
48	O
].	O

However	O
,	O
it	O
is	O
known	O
that	O
inflammation	O
profoundly	O
affects	O
the	O
development	O
and	O
progression	O
of	O
tumor	B-DS
and	O
therefore	O
,	O
IL	B-GP
-	I-GP
8	I-GP
might	O
promote	O
tumor	B-DS
cell	O
proliferation	O
by	O
amplification	O
of	O
inflammation	O
in	O
the	O
tumor	B-DS
microenvironnement	O
via	O
its	O
receptors	O
.	O

IL	B-GP
-	I-GP
8	I-GP
proangiogenic	O
effects	O
additionally	O
stem	O
from	O
its	O
ability	O
to	O
inhibit	O
the	O
apoptosis	O
of	O
endothelial	O
cells	O
[	O
49	O
].	O

This	O
inhibition	O
is	O
associated	O
with	O
increased	O
levels	O
of	O
the	O
anti	O
-	O
apoptotic	O
factors	O
Bcl	B-GP
-	I-GP
xl	I-GP
and	O
Bcl	B-GP
-	I-GP
2	I-GP
as	O
well	O
as	O
with	O
decreased	O
levels	O
of	O
Bax	B-GP
.	O

It	O
was	O
further	O
shown	O
that	O
IL	B-GP
-	I-GP
8	I-GP
stimulates	O
increased	O
endothelial	O
cell	O
mRNA	O
expression	O
of	O
matrix	B-GP
metalloproteinases	I-GP
(	O
MMPs	B-GP
)	O
MMP	B-GP
-	I-GP
2	I-GP
and	O
-	O
9	O
as	O
well	O
as	O
increases	O
gelatine	O
activity	O
[	O
49	O
].	O

These	O
MMP	B-GP
activities	O
are	O
required	O
for	O
the	O
proteolytic	O
modifications	O
of	O
basements	O
membranes	O
and	O
extracellular	O
matrices	O
during	O
angiogenesis	O
.	O

IL	B-GP
-	I-GP
8	I-GP
was	O
shown	O
to	O
act	O
as	O
an	O
autocrine	O
growth	O
factor	O
and	O
to	O
stimulate	O
invasion	O
and	O
chemotaxis	O
of	O
many	O
tumor	B-DS
cell	O
types	O
.	O

The	O
expression	O
of	O
IL	B-GP
-	I-GP
8	I-GP
and	O
the	O
receptor	O
of	O
ELR	O
+	O
CXC	B-GP
chemokine	I-GP
CXCR2	B-GP
in	O
cancer	B-DS
have	O
been	O
evaluated	O
in	O
numerous	O
studies	O
.	O

Overexpression	O
of	O
IL	B-GP
-	I-GP
8	I-GP
is	O
associated	O
with	O
increasing	O
tumor	B-DS
stage	O
,	O
disease	O
progression	O
and	O
recurrence	O
in	O
human	B-OG
bladder	O
,	O
prostate	O
,	O
breast	O
,	O
lung	O
,	O
gastric	O
,	O
hepatic	B-DS
cancers	I-DS
,	O
and	O
melanoma	B-DS
[	O
11	O
,	O
14	O
-	O
16	O
,	O
43	O
,	O
50	O
,	O
51	O
].	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
ER	B-DS
-	I-DS
negative	I-DS
breast	I-DS
cancer	I-DS
cells	O
overexpressed	O
IL	B-GP
-	I-GP
8	I-GP
.	O

Concerning	O
IL	B-GP
-	I-GP
8	I-GP
receptors	I-GP
,	O
it	O
has	O
been	O
observed	O
that	O
CXCR1	B-GP
expression	O
was	O
extremely	O
low	O
in	O
breast	B-DS
cancer	I-DS
cells	O
,	O
whereas	O
most	O
of	O
the	O
cells	O
investigated	O
showed	O
a	O
higher	O
expression	O
of	O
CXCR2	B-GP
[	O
52	O
].	O

The	O
same	O
study	O
also	O
suggested	O
that	O
IL	B-GP
-	I-GP
8	I-GP
expression	O
is	O
negatively	O
correlated	O
to	O
ER	O
-	O
status	O
and	O
is	O
expressed	O
preferentially	O
in	O
invasive	B-DS
cancer	I-DS
cells	O
[	O
52	O
].	O

Moreover	O
,	O
our	O
data	O
showed	O
that	O
the	O
higher	O
percentage	O
of	O
ER	O
-	O
negative	O
tumors	B-DS
were	O
present	O
in	O
patients	O
carrying	O
the	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
A	O
allele	O
which	O
is	O
associated	O
with	O
a	O
higher	O
IL	B-GP
-	I-GP
8	I-GP
production	O
.	O

Altogether	O
,	O
these	O
results	O
suggested	O
that	O
the	O
genetic	O
variation	O
in	O
the	O
promoter	O
of	O
the	O
IL	B-GP
-	I-GP
8	I-GP
gene	O
which	O
influences	O
the	O
production	O
of	O
this	O
chemokine	B-GP
could	O
be	O
the	O
genetic	O
basis	O
of	O
the	O
potential	O
tumor	B-DS
progression	O
and	O
invasiveness	O
of	O
breast	B-DS
cancer	I-DS
.	O

The	O
ability	O
of	O
IL	B-GP
-	I-GP
8	I-GP
to	O
elicit	O
angiogenic	O
activity	O
depends	O
on	O
the	O
endothelial	O
cell	O
expression	O
of	O
its	O
receptors	O
.	O

Recent	O
studies	O
indicated	O
that	O
CXCR1	B-GP
and	O
CXCR2	B-GP
are	O
highly	O
expressed	O
on	O
human	B-OG
microvascular	O
endothelial	O
cells	O
(	O
HMEC	O
)	O
[	O
53	O
].	O

Antibodies	O
directed	O
at	O
CXCR1	B-GP
and	O
CXCR2	B-GP
are	O
capable	O
of	O
inhibiting	O
IL	B-GP
-	I-GP
8	I-GP
induced	O
migration	O
of	O
HMEC	O
,	O
which	O
indicates	O
that	O
these	O
two	O
receptors	O
are	O
critical	O
for	O
the	O
IL	B-GP
-	I-GP
8	I-GP
angiogenic	O
response	O
.	O

Since	O
CXCR2	B-GP
binds	O
to	O
all	O
ELR	O
+	O
CXC	B-GP
chemokines	I-GP
that	O
induce	O
angiogenesis	O
,	O
including	O
IL	B-GP
-	I-GP
8	I-GP
,	O
it	O
may	O
be	O
safe	O
to	O
say	O
that	O
CXCR2	B-GP
is	O
a	O
mediator	O
of	O
the	O
proangiogenic	O
effects	O
of	O
IL	B-GP
-	I-GP
8	I-GP
.	O

Several	O
reports	O
have	O
confirmed	O
the	O
importance	O
of	O
CXCR2	B-GP
in	O
mediating	O
the	O
effects	O
of	O
angiogenesis	O
in	O
human	B-OG
microvascular	O
endothelial	O
cells	O
[	O
18	O
,	O
36	O
,	O
53	O
].	O

Endothelial	O
cells	O
were	O
found	O
to	O
express	O
CXCR2	B-GP
in	O
vitro	O
and	O
in	O
vivo	O
,	O
but	O
not	O
CXCR1	B-GP
.	O

Blocking	O
the	O
function	O
of	O
CXCR2	B-GP
by	O
either	O
neutralizing	O
antibodies	O
or	O
inhibiting	O
downstream	O
signalling	O
using	O
specific	O
inhibitors	O
of	O
ERK1	B-GP
/	O
2	O
and	O
PI3	B-GP
kinase	I-GP
impaired	O
IL	B-GP
-	I-GP
8	I-GP
-	O
induced	O
stress	O
fiber	O
assembly	O
,	O
chemotaxis	O
,	O
and	O
endothelial	O
tube	O
formation	O
in	O
endothelial	O
cells	O
[	O
39	O
,	O
54	O
].	O

Overall	O
,	O
these	O
data	O
strongly	O
support	O
a	O
role	O
for	O
CXCR2	B-GP
in	O
angiogenesis	O
induced	O
by	O
ELR	O
+	O
CXC	B-GP
chemokines	I-GP
and	O
especially	O
by	O
IL	B-GP
-	I-GP
8	I-GP
.	O

Conclusion	O

In	O
summary	O
,	O
our	O
data	O
suggests	O
that	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
T	O
/	O
A	O
and	O
CXCR2	B-GP
(+	O
1208	O
)	O
C	O
/	O
T	O
polymorphisms	O
are	O
likely	O
to	O
play	O
a	O
major	O
role	O
in	O
susceptibility	O
to	O
and	O
prognosis	O
in	O
breast	B-DS
carcinoma	I-DS
.	O

Although	O
additional	O
studies	O
on	O
a	O
larger	O
scale	O
will	O
be	O
required	O
to	O
confirm	O
and	O
extend	O
our	O
findings	O
,	O
the	O
present	O
data	O
suggest	O
for	O
the	O
first	O
time	O
that	O
CXCR2	B-GP
(+	O
1208	O
)	O
C	O
/	O
T	O
polymorphism	O
represents	O
a	O
risk	O
factor	O
for	O
poorer	O
prognosis	O
and	O
susceptibility	O
to	O
breast	B-DS
carcinoma	I-DS
.	O

Furthermore	O
,	O
this	O
study	O
provides	O
support	O
for	O
the	O
multigenetic	O
effects	O
of	O
the	O
variant	O
alleles	O
from	O
IL	B-GP
-	I-GP
8	I-GP
,	O
and	O
CXCR2	B-GP
,	O
resulting	O
in	O
a	O
significantly	O
increased	O
risk	O
for	O
breast	B-DS
cancer	I-DS
in	O
the	O
Tunisian	O
population	O
.	O

Our	O
findings	O
also	O
reinforce	O
the	O
role	O
attributed	O
to	O
inflammation	O
,	O
angiogenesis	O
,	O
and	O
their	O
mediators	O
as	O
major	O
contributing	O
factors	O
in	O
the	O
process	O
of	O
breast	B-DS
tumor	I-DS
development	O
,	O
progression	O
and	O
aggressiveness	O
.	O

Using	O
the	O
IL	B-GP
-	I-GP
8	I-GP
(-	O
251	O
)	O
T	O
/	O
A	O
and	O
CXCR2	B-GP
(+	O
1208	O
)	O
C	O
/	O
T	O
polymorphisms	O
alone	O
or	O
in	O
combination	O
with	O
other	O
genetic	O
polymorphisms	O
in	O
angiogenic	O
and	O
inflammatory	O
genes	O
to	O
predict	O
breast	B-DS
carcinoma	I-DS
outcome	O
and	O
prognosis	O
may	O
therefore	O
have	O
an	O
important	O
clinical	O
significance	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

SK	O
conceived	O
the	O
manuscript	O
,	O
conducted	O
data	O
analysis	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O

MW	O
contributed	O
to	O
the	O
design	O
and	O
management	O
of	O
data	O
.	O

HK	O
,	O
MF	O
and	O
NB	O
provided	O
samples	O
and	O
clinical	O
information	O
.	O

LC	O
designed	O
and	O
participated	O
in	O
the	O
data	O
analysis	O
and	O
interpretation	O
of	O
the	O
study	O
.	O

AN	O
-	O
H	O
contributed	O
to	O
reviewing	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

http	O
://	O
www	O
.	O
biomedcentral	O
.	O
com	O
/	O
1471	O
-	O
2407	O
/	O
10	O
/	O
283	O
/	O
prepub	O

